

<p style="text-align: right;">Page 5</p> <p>1 CONTENTS</p> <p>2</p> <p>3 EXAMINATION OF CLAUDE DUBOIS: PAGE</p> <p>4 BY MR. STEWART 11</p> <p>5 BY MR. BOSTWICK 118</p> <p>6 BY MR. STEWART 159</p> <p>7</p> <p>8 DEPOSITION EXHIBIT: Page Identified:</p> <p>9 1 Letter, 1/20/97, de Basilio to</p> <p>10 Gonzalez, EP 006617, with English</p> <p>11 translation 47</p> <p>12 2 Letter, 1/28/97, Murphy to Debregas,</p> <p>13 EP 002450, with English translation 49</p> <p>14 3 Fax with Letter, 2/14/97, from</p> <p>15 Dubois and Audit of the Ethypharm</p> <p>16 Production Site in Zaragoza.</p> <p>17 EP 004676 - 682 58</p> <p>18 4 Draft, 14 March 1995, Memorandum of</p> <p>19 Understanding, EP 009082 - 9091,</p> <p>20 with English translation of 9082 64</p> <p>21 5 Faxed Agreement, 7/13/95, EP 009008</p> <p>22 - 9022 64-65</p>	<p style="text-align: right;">Page 7</p> <p>1 CONTENTS (Contents)</p> <p>2</p> <p>3 DEPOSITION EXHIBIT: Page Identified:</p> <p>4 12 Ethypharm document, 10/2/98,</p> <p>5 EP 008124 102, 109</p> <p>6 13 Contrato de Fabricacion, BEL000548</p> <p>7 - 553 114</p> <p>8 14 Carta de Compromiso de Compra</p> <p>9 EP 004863 - 865, A-96 - A-97 118</p> <p>10 15 EP 002124 127</p> <p>11 16 EP 002442 - 443 129</p> <p>12 17 Letter, 2/13/97, Dubois to Murphy</p> <p>13 EP 004677 - 681 144</p> <p>14 18 Letter, undated, Murphy to Dubois</p> <p>15 EP 002445 146</p> <p>16 19 Fax, 3/31/98, Ethypharm to Belmac,</p> <p>17 EP 003259 - 261 152</p> <p>18 20 Fax, 4/6/98, de Basilio to Murphy</p> <p>19 EP 003262, 628, 629 153</p> <p>20 21 Letter, 3/20/97, Gonzalez to "Monsieur"</p> <p>21 EP 002440 - 441, with English</p> <p>22 translation 170, 176</p>
<p style="text-align: right;">Page 6</p> <p>1 CONTENTS (Contents)</p> <p>2 DEPOSITION EXHIBIT: Page Identified:</p> <p>3 6 Letter, 9/3/97, Gonzalez to Dubois</p> <p>4 EP 002462 - 465, with English</p> <p>5 translation 68</p> <p>6 7 Contrato de Fabricacion por</p> <p>7 Terceros de Productos Farmaceuticos</p> <p>8 BEL006381 - 388 71</p> <p>9 8 Contrato de Fabricacion por</p> <p>10 Terceros de Productos Farmaceuticos</p> <p>11 BEL006372 - 379 71</p> <p>12 9 Draft contract sent by Ethypharm</p> <p>13 Spain to Belmac Spain, beginning of</p> <p>14 September, BEL006371 - 396, with</p> <p>15 one page, English translation 71</p> <p>16 10 Certificate from Laboratorios</p> <p>17 Belmac signed by Mr. Gonzalez</p> <p>18 EP 008092 102-103</p> <p>19 11 Confidentiality Agreement,</p> <p>20 Ethypharm Spain and Belmac</p> <p>21 BEL000601 - 603 with English</p> <p>22 translation 102, 106</p>	<p style="text-align: right;">Page 8</p> <p>1 CONTENTS (Contents)</p> <p>2</p> <p>3 DEPOSITION EXHIBIT: Page Identified:</p> <p>4 22 Letter, 4/1/97, Dubois to "Sir"</p> <p>5 EP 002769 with English translation 170</p> <p>6 23 Letter, 4/9/97, Dubois to Murphy</p> <p>7 EP 002446 170</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p>

2 (Pages 5 to 8)

<p style="text-align: right;">Page 9</p> <p>1 PROCEEDINGS</p> <p>2 * * * * *</p> <p>3</p> <p>4 THE VIDEOGRAPHER: On the record with</p> <p>5 Tape No. 1 of the videotape deposition of Claude</p> <p>6 Dubois taken by the defendant in the matter of</p> <p>7 Ethypharm S.A. France and Ethypharm S.A. Spain</p> <p>8 versus Bentley Pharmaceuticals, Incorporated, in</p> <p>9 the United States District Court for the District</p> <p>10 of Delaware, Civil Action No. 04-1300-SLR.</p> <p>11 This deposition is being taken at the</p> <p>12 law offices of Baach, Robinson & Lewis located at</p> <p>13 1201 F Street, Northwest, in Washington, D.C., on</p> <p>14 July 12th, 2006 at approximately 10:11 a.m.</p> <p>15 My name is T.J. O'Toole representing</p> <p>16 Esquire Deposition Services. I am the certified</p> <p>17 legal video specialist. The court reporter is</p> <p>18 Marijane Simon also representing Esquire</p> <p>19 Deposition Services. Will counsel please</p> <p>20 introduce themselves and indicate which parties</p> <p>21 they represent.</p> <p>22 MR. STEWART: Craig Stewart and Joseph</p>	<p style="text-align: right;">Page 11</p> <p>1 notary, was examined and testified as follows:</p> <p>2 EXAMINATION BY COUNSEL FOR THE DEFENDANT</p> <p>3 BY MR. STEWART:</p> <p>4 Q. Good morning, Mr. Dubois.</p> <p>5 THE WITNESS (IN FRENCH): Bonjour.</p> <p>6 BY MR. STEWART:</p> <p>7 Q. My name is Craig Stewart as you heard</p> <p>8 and I represent the defendant in this case. And</p> <p>9 the defendant is Bentley Pharmaceuticals,</p> <p>10 Incorporated.</p> <p>11 Before we begin, have you had your</p> <p>12 deposition taken before?</p> <p>13 A. No.</p> <p>14 Q. You'll be giving testimony today under</p> <p>15 oath and that means that there are penalties under</p> <p>16 U.S. law if your statements are not truthful.</p> <p>17 Do you understand?</p> <p>18 A. Yes.</p> <p>19 Q. Okay. And as you provide your</p> <p>20 testimony, you must give a verbal response to the</p> <p>21 questions. Do you understand?</p> <p>22 A. Yes.</p>
<p style="text-align: right;">Page 10</p> <p>1 Mingolla, Edwards, Angell, Palmer & Dodge for the</p> <p>2 Defendant, Bentley Pharmaceuticals, Inc.</p> <p>3 MR. BOSTWICK: Dwight Bostwick for the</p> <p>4 plaintiffs in this action, Ethypharm and Ethypharm</p> <p>5 S.A. Spain.</p> <p>6 THE VIDEOGRAPHER: Thank you.</p> <p>7 Will the court reporter please swear in</p> <p>8 the interpreter. I'm sorry. Will the interpreter</p> <p>9 please identify himself and then the court</p> <p>10 reporter swear him in.</p> <p>11 THE INTERPRETER: I am Didier Devynck</p> <p>12 and I am the interpreter.</p> <p>13 DIDIER DEVYNCK,</p> <p>14 was sworn to interpret from English into French</p> <p>15 and French into English to the best of his</p> <p>16 ability.</p> <p>17 THE VIDEOGRAPHER: Thank you.</p> <p>18 Will the court reporter please swear in</p> <p>19 the witness.</p> <p>20 Thereupon,</p> <p>21 CLAUDE DUBOIS,</p> <p>22 after having been duly sworn (or affirmed) by the</p>	<p style="text-align: right;">Page 12</p> <p>1 Q. So nods of the head one -- one way or</p> <p>2 the other cannot be taken down.</p> <p>3 A. Understood.</p> <p>4 Q. If you need to take a break from the</p> <p>5 questions, please say so. The exception will be</p> <p>6 if I have a question that I've asked of you and</p> <p>7 you have not yet answered.</p> <p>8 A. Okay.</p> <p>9 Q. Yes. And -- And by agreement, when we</p> <p>10 take a break from the questions -- that you are</p> <p>11 not permitted to speak to your counsel,</p> <p>12 Mr. Bostwick, concerning the substance of your</p> <p>13 testimony.</p> <p>14 Do you understand?</p> <p>15 A. Yes.</p> <p>16 Q. Now, you speak English; is that</p> <p>17 correct?</p> <p>18 A. Yes.</p> <p>19 Q. And do you read English?</p> <p>20 A. Yes.</p> <p>21 Q. And do you write English?</p> <p>22 A. Yes.</p>

3 (Pages 9 to 12)

<p style="text-align: right;">Page 13</p> <p>1 Q. Do you speak Spanish?</p> <p>2 A. A little.</p> <p>3 Q. Do you read Spanish?</p> <p>4 A. Yes.</p> <p>5 Q. And do you write Spanish?</p> <p>6 A. Not very well.</p> <p>7 Q. All right. It is up to you as to</p> <p>8 whether you will need to -- whether you want to or</p> <p>9 will need to use the services of Monsieur Devynck.</p> <p>10 A. I prefer.</p> <p>11 Q. Fine. By whom are you employed?</p> <p>12 A. Today?</p> <p>13 Q. Yes.</p> <p>14 A. Ambrilia BioPharma.</p> <p>15 Q. Could you spell that, please.</p> <p>16 A. A-m-b --</p> <p>17 Q. A-m-b?</p> <p>18 A. -- r -- r-o -- No. Sorry -- r-i --</p> <p>19 l-i-a. BioPharma.</p> <p>20 Q. Bureau?</p> <p>21 A. Bio.</p> <p>22 Q. Bio?</p>	<p style="text-align: right;">Page 15</p> <p>1 BY MR. STEWART:</p> <p>2 Q. What are your duties?</p> <p>3 A. Business -- Business development,</p> <p>4 license agreements, partnerships, business</p> <p>5 negotiations.</p> <p>6 Q. What is the business of Ambrilia</p> <p>7 BioPharma?</p> <p>8 A. Research, research and development, of</p> <p>9 new pharmaceutical products.</p> <p>10 Q. And what was the business of Cellpep</p> <p>11 S.A.?</p> <p>12 A. Research and development of new drugs,</p> <p>13 peptids in particular.</p> <p>14 Q. Where were you employed before your</p> <p>15 employment with Cellpep?</p> <p>16 A. With Ethypharm.</p> <p>17 Q. With Ethypharm France or Ethypharm</p> <p>18 Spain?</p> <p>19 A. France.</p> <p>20 Q. Where were your offices?</p> <p>21 A. In St. Cloud, France.</p> <p>22 Q. What was your position?</p>
<p style="text-align: right;">Page 14</p> <p>1 A. B-i-o, Pharma, P-h-a-r-m-a.</p> <p>2 Q. How long have you been employed by</p> <p>3 Ambril -- Ambrilia BioPharma?</p> <p>4 A. I've been employed there for six years</p> <p>5 but the company merged with Ambrilia Bio --</p> <p>6 BioPharma.</p> <p>7 Q. When did you start your job with --</p> <p>8 What was -- I withdraw that.</p> <p>9 What was the name of the company</p> <p>10 before it merged with Ambrilia?</p> <p>11 A. Cellpep.</p> <p>12 Q. Spell?</p> <p>13 A. C-e-l-l-p-e-p. Oh. S.A.</p> <p>14 Q. Cellpep S.A. And when did you start</p> <p>15 your employment with Cellpep?</p> <p>16 A. July 2000.</p> <p>17 Q. What is your current position with</p> <p>18 Ambrilia BioPharma?</p> <p>19 A. Business development director --</p> <p>20 THE WITNESS (IN ENGLISH): Senior</p> <p>21 director.</p> <p>22 THE INTERPRETER: Senior director.</p>	<p style="text-align: right;">Page 16</p> <p>1 A. Vice president for operations.</p> <p>2 Q. When did you begin your employment</p> <p>3 with Ethypharm?</p> <p>4 A. December -- December Ninety -- 1993 as</p> <p>5 a part-time consultant, and one year later, full</p> <p>6 time as VP, operations.</p> <p>7 Q. What was the reason that you left</p> <p>8 Ethypharm France?</p> <p>9 A. Strategic discrepancies with one of</p> <p>10 the owners about the products to be developed.</p> <p>11 Q. Which owner?</p> <p>12 A. Patrice Debregeas.</p> <p>13 Q. Were you asked to leave?</p> <p>14 A. Yes.</p> <p>15 Q. When were you asked to leave?</p> <p>16 A. January 2000.</p> <p>17 Q. When was your last day at Ethypharm</p> <p>18 France?</p> <p>19 A. I believe -- I believe it was</p> <p>20 June 30th, 2000, officially. I was paid until</p> <p>21 June 30th, 2000.</p> <p>22 Q. And when did you last do work for</p>

4 (Pages 13 to 16)

<p style="text-align: right;">Page 17</p> <p>1 Ethypharm France.</p> <p>2 A. Beginning, mid February.</p> <p>3 Q. Do you have a -- Do you personally --</p> <p>4 Do you personally have a business -- any business</p> <p>5 dealings with Ethypharm France at the present</p> <p>6 time?</p> <p>7 A. No.</p> <p>8 Q. Are you being paid as a consultant to</p> <p>9 Ethypharm France?</p> <p>10 A. No.</p> <p>11 Q. Has Ethypharm France paid your</p> <p>12 expenses in your coming to the United States for</p> <p>13 this deposition?</p> <p>14 A. I believe so, yes.</p> <p>15 Q. Did you buy the plane ticket yourself?</p> <p>16 A. No.</p> <p>17 Q. Are you currently receiving any</p> <p>18 compensation from Ethypharm France other than the</p> <p>19 payment of your expenses?</p> <p>20 A. No.</p> <p>21 Q. What is your residence address, sir?</p> <p>22 A. 25 Chemin, C-h-e-m-i-n, du, d-u, Bois,</p>	<p style="text-align: right;">Page 19</p> <p>1 A. The two -- The two owners.</p> <p>2 Q. That would be Mis -- Monsieur Leduc</p> <p>3 and Monsieur Debregas?</p> <p>4 A. That's it.</p> <p>5 Q. Okay. Tell me your duties as vice</p> <p>6 president of operations from December of 1994</p> <p>7 until you left.</p> <p>8 A. I was in charge of all the development</p> <p>9 of the company, the business operations. All the</p> <p>10 directions were reporting to me.</p> <p>11 Q. All the? All the?</p> <p>12 A. Directions. The departments.</p> <p>13 THE WITNESS (IN ENGLISH): Departments.</p> <p>14 THE INTERPRETER: That is to say,</p> <p>15 business, medical -- oh, registration and</p> <p>16 development of new products. The only functions</p> <p>17 that were not depending upon me were finance and</p> <p>18 administration and manufacturing in France. All</p> <p>19 the subsidiaries were under me.</p> <p>20 BY MR. STEWART:</p> <p>21 Q. And was one of the subsidiaries</p> <p>22 Ethypharm Spain S.A.?</p>
<p style="text-align: right;">Page 18</p> <p>1 B-o-i-s, des, d-e-s, Arpents, A-r-p-e-n-t-s,</p> <p>2 78860, S-t -- That's Saint -- S-t -- Nom, N-o-m,</p> <p>3 as in Mary, La, L-a, Brete, B-r-e-t-e, accent</p> <p>4 grave, c-h-e -- France.</p> <p>5 Q. La Breteche, France?</p> <p>6 A. C-h-e.</p> <p>7 Q. C-h-e. Grave?</p> <p>8 Who -- By whom were you employed</p> <p>9 before Ethypharm?</p> <p>10 A. Before I was a consultant?</p> <p>11 Q. Yes.</p> <p>12 A. Laboratoire Debat, D-e-b-a-t.</p> <p>13 Q. Debat. What business was Laboratoire</p> <p>14 Debois -- Debat in?</p> <p>15 A. Pharmaceutical products.</p> <p>16 Q. Was your title in 1994 vice president</p> <p>17 of operations?</p> <p>18 A. At the end of the year, yes, when I</p> <p>19 became full-time.</p> <p>20 Q. And when did you become full time?</p> <p>21 A. I think it was December 1994.</p> <p>22 Q. Who hired you?</p>	<p style="text-align: right;">Page 20</p> <p>1 A. Yes.</p> <p>2 Q. Who at Ethypharm Spain S.A. did you</p> <p>3 have contact with?</p> <p>4 A. With all the employees of Ethypharm</p> <p>5 Spain but in all -- in particular, of course, the</p> <p>6 director, Adolfo de Basilio.</p> <p>7 Q. And did Adolfo de Basilio report</p> <p>8 directly to you?</p> <p>9 A. Yes.</p> <p>10 Q. How often would you confer with Adolfo</p> <p>11 de Basilio during the course of a week?</p> <p>12 A. Some weeks, several times; some other</p> <p>13 weeks, no contact at all.</p> <p>14 Q. Did you have regularly scheduled</p> <p>15 meetings with Mr. De Basilio?</p> <p>16 A. Yes.</p> <p>17 Q. When were those meetings scheduled</p> <p>18 for?</p> <p>19 A. About once a month, either by phone or</p> <p>20 in Paris or in Spain.</p> <p>21 Q. Where were Ethypharm Spain's offices?</p> <p>22 A. In Madrid. I don't remember the</p>

5 (Pages 17 to 20)

<p style="text-align: right;">Page 21</p> <p>1 address but I could go there with my eye closed 2 today. 3 Q. How often did you visit Ethypharm 4 Spain? 5 A. Yes, I don't know how many times but 6 dozens of times, maybe. 7 Q. What was Mr. De Basilio's authority 8 with regard to decisions concerning Ethypharm 9 Spain? 10 A. He was the general manager and he had 11 the authority of a general manager. 12 Q. What decisions did Mr. De Basilio 13 require your approval for? 14 A. Decisions having to do with business 15 negotiation; especially when the price was 16 different, and also decisions having to do with 17 contract negotiations. 18 MR. BOSTWICK: And, perhaps, a helpful 19 comment. If you give a long answer, and you're 20 going to give it in French rather than English, 21 you may need to pause for the translator. 22 ...</p>	<p style="text-align: right;">Page 23</p> <p>1 Q. Did you -- Were you involved in 2 negotiating the price that Ethypharm -- Let me 3 withdraw that. 4 Were you involved with negotiating the 5 price that Laboratorios Belmac charged Ethypharm 6 for manufacture of Omeprazole? 7 A. Yes. 8 Q. And were you also involved in 9 negotiating price and the price which Ethypharm 10 charged Lab -- Laboratorios Belmac for the supply 11 of Omeprazole? 12 A. I was informed but there were no 13 negotiations. It was a common price for all of 14 the partners although Belmac had a -- a slight 15 discount compared to the common price. 16 Q. Were you ever involved in matters 17 concerning quality assurance at the facility of 18 Laboratorios Belmac? 19 A. Yes, I requested twice audits. 20 Q. Were those audits requested by you or 21 by Adolfo de Basilio? 22 A. By me because they were performed by</p>
<p style="text-align: right;">Page 22</p> <p>1 BY MR. STEWART: 2 Q. Did you -- During the time that you 3 were vice president of operations, were you aware 4 of a company called Laboratorios Belmac S.A.? 5 A. Yes, naturally. 6 Q. And did you understand that 7 Laboratorios Belmac was a subsidiary of Bentley 8 Pharmaceuticals, Incorporated? 9 A. At the beginning -- At the beginning, 10 it was a subsidiary of Belmac Corporation, United 11 States, then it changed its name to Bentley 12 Corporation, I believe, in 1996. 13 Q. Were you involved in matters 14 concerning the production of Omeprazole by 15 Laboratory Belmac -- by Laboratorios Belmac? 16 MR. BOSTWICK: Objection to form. 17 THE WITNESS: Yes, I was involved. 18 BY MR. STEWART: 19 Q. What was the nature of your 20 involvement? 21 A. To do -- do things so that it would 22 work.</p>	<p style="text-align: right;">Page 24</p> <p>1 France. 2 Q. Were you involved in dealing with 3 customers of Ethypharm Spain? 4 A. Yes. 5 Q. Were you involved in the transfer of 6 technology from Ethypharm France to -- and -- 7 Withdraw that. 8 Did you become involved in the 9 transfer of Ethypharm's technology to Laboratorios 10 Belmac? 11 A. Technology transfer is -- is an 12 ongoing process. The largest part had been done 13 before my arrival. And during the year -- During 14 the years I was there, we had to re -- Hmmh -- 15 re -- re -- readjust fabrications -- 16 THE WITNESS (IN ENGLISH): Reengineer. 17 THE INTERPRETER: -- reengineer 18 fabrications, manufacturing. And I was involved 19 at that point. 20 BY MR. STEWART: 21 Q. Were you involved in requesting 22 confidentiality agreements from anyone in</p>

6 (Pages 21 to 24)

<p style="text-align: right;">Page 25</p> <p>1 connection with Ethypharm technology?</p> <p>2 A. Yes.</p> <p>3 Q. What was your involvement?</p> <p>4 A. The whole -- The whole Ethypharm</p> <p>5 company was involved-- was concerned about this</p> <p>6 confi -- confidentiality. My responsibility was</p> <p>7 to make sure that Adolfo de Basilio follow and</p> <p>8 signed on this responsibility -- this</p> <p>9 confidentiality --</p> <p>10 THE WITNESS (IN ENGLISH): Obtain,</p> <p>11 obtain.</p> <p>12 THE INTERPRETER: -- obtain it.</p> <p>13 BY MR. STEWART:</p> <p>14 Q. What other aspects of the relationship</p> <p>15 between Ethypharm Spain and Laboratorios Belmac</p> <p>16 were you involved?</p> <p>17 MR. BOSTWICK: Objection. Form.</p> <p>18 Vague.</p> <p>19 THE INTERPRETER: Do I translate?</p> <p>20 MR. STEWART: Yes.</p> <p>21 THE INTERPRETER: Okay.</p> <p>22 THE WITNESS: I do not understand the</p>	<p style="text-align: right;">Page 27</p> <p>1 And, of course, at the Ethypharm</p> <p>2 headquarters in Madrid, there was a --</p> <p>3 Q. Does he mean Ethypharm headquarters or</p> <p>4 Laboratorios Belmac?</p> <p>5 THE WITNESS (In English): Belmac</p> <p>6 headquarters.</p> <p>7 THE INTERPRETER: Belmac headquarters.</p> <p>8 There were the normal administrative team.</p> <p>9 BY MR. STEWART:</p> <p>10 Q. At any time did you know the number of</p> <p>11 employees employed by Bentley Pharmaceuticals in</p> <p>12 the United States?</p> <p>13 A. No, I believe there was only a -- a</p> <p>14 major staff.</p> <p>15 Q. Only a --</p> <p>16 A. Tough staff, senior staff.</p> <p>17 Q. Who at Laboratorios Belmac did you</p> <p>18 have direct contact with?</p> <p>19 A. Mainly, Mr. Gonzalez, Clemente</p> <p>20 Gonzalez; Mr. Berenguer.</p> <p>21 Q. What was Mr. Berenguer's position?</p> <p>22 A. Legal and administrative director. Of</p>
<p style="text-align: right;">Page 26</p> <p>1 question very well.</p> <p>2 MR. STEWART: Sure.</p> <p>3 BY MR. STEWART:</p> <p>4 Q. Were there any other activities that</p> <p>5 you had specif -- that you had specific</p> <p>6 involvement in, activities that were between</p> <p>7 Ethypharm Spain and Laboratorios Belmac?</p> <p>8 A. The only activities that were between</p> <p>9 Belmac Spain and -- and Ethypharm Spain were that</p> <p>10 Belmac was manufacturing products for Ethypharm</p> <p>11 and so it was just contract manufacturing. And,</p> <p>12 of course, Belmac was a customer of Ethypharm</p> <p>13 Spain for Omeprazole.</p> <p>14 Q. How many employees did Laboratorios</p> <p>15 Belmac have, to your knowledge?</p> <p>16 A. It is difficult to answer this</p> <p>17 question because in the plant, I believe, there</p> <p>18 were maybe 50 or 60 people. Gradually, Belmac has</p> <p>19 developed business teams, and I don't know how</p> <p>20 many representatives they had in Spain, and it</p> <p>21 grew; and to cover the Spanish market, it probably</p> <p>22 takes about 70 or 80 representatives.</p>	<p style="text-align: right;">Page 28</p> <p>1 course, I had contacts with Mateo Gasca.</p> <p>2 Q. What was Mr. Gasca's position as you</p> <p>3 understood it?</p> <p>4 A. Mr. Gasca had to do -- Mainly, he was</p> <p>5 responsible for manufacturing, especially for the</p> <p>6 Ethypharm product. He all -- He also had quality</p> <p>7 control responsibilities. He was responsible for</p> <p>8 all the quality control for the Zaragoza plant,</p> <p>9 the Belmac Zaragoza plant until, following our</p> <p>10 inspections, somebody else -- somebody else was in</p> <p>11 charge of the quality control. I believe</p> <p>12 Mr. Cabodevilla.</p> <p>13 And, of course, I had contact with</p> <p>14 Mr. Monterde, the manufacturing manager at</p> <p>15 Belmac --</p> <p>16 THE WITNESS (IN ENGLISH): Plant</p> <p>17 manager.</p> <p>18 THE INTERPRETER: Plant manager, yeah.</p> <p>19 And, of course, in the later years,</p> <p>20 contacts with Mr. Adolfo Herrera who eventually</p> <p>21 replaced Mr. Gonzalez.</p> <p>22 ...</p>

7 (Pages 25 to 28)

<p style="text-align: right;">Page 29</p> <p>1 BY MR. STEWART:</p> <p>2 Q. Did you have any contact with Juan</p> <p>3 Carlos Asensio?</p> <p>4 A. No, I don't remember.</p> <p>5 Q. Okay. And did you have any contact</p> <p>6 with Jose-Maria Esteve?</p> <p>7 A. I know one Jose-Maria Esteve who is a</p> <p>8 founder and a general manager of the Esteve</p> <p>9 Laboratories but I don't think it's the same one.</p> <p>10 Q. Did you have any dealings with</p> <p>11 Miss Concha Sanchez? Sanchez.</p> <p>12 THE INTERPRETER: Sanchez.</p> <p>13 THE WITNESS: The name seems familiar.</p> <p>14 Maybe it was Mr. Gonzalez's assistant. I don't</p> <p>15 recall.</p> <p>16 BY MR. STEWART:</p> <p>17 Q. What was the nature of your contacts</p> <p>18 between yourself and Clemente Gonzalez?</p> <p>19 A. I was trying to negotiate the</p> <p>20 manufacturing contract which was on hold when I</p> <p>21 arrived at the head of the Ethypharm operations.</p> <p>22 Q. Any other contacts -- Any other</p>	<p style="text-align: right;">Page 31</p> <p>1 THE WITNESS: The negotiations were</p> <p>2 completed. We were agreeing on the principle</p> <p>3 since 1997 but the legal documents have not been</p> <p>4 done until the time of my leaving.</p> <p>5 BY MR. STEWART:</p> <p>6 Q. Until after?</p> <p>7 THE WITNESS (IN ENGLISH): About the</p> <p>8 time of my leaving. I believe just after.</p> <p>9 THE INTERPRETER: Just about that</p> <p>10 time. I believe -- I believe just after I left.</p> <p>11 MR. STEWART: I may have misunderstood</p> <p>12 your translation. You translated a phrase that</p> <p>13 Mr. Dubois used and I think you said that the</p> <p>14 negotiations -- that there was something in</p> <p>15 principle since 1997.</p> <p>16 THE INTERPRETER: Right.</p> <p>17 MR. STEWART: I didn't understand what</p> <p>18 you --</p> <p>19 MR. BOSTWICK: Do you want to read</p> <p>20 back the answer?</p> <p>21 MR. STEWART: Yeah, that would</p> <p>22 probably be best.</p>
<p style="text-align: right;">Page 30</p> <p>1 specific purposes of contacts with Mr. Gonzalez</p> <p>2 that you can recall?</p> <p>3 MR. BOSTWICK: Objection. Form.</p> <p>4 THE WITNESS: I intervened during</p> <p>5 negotiations that were stalled to unstage them.</p> <p>6 BY MR. STEWART:</p> <p>7 Q. And what was the nature of your</p> <p>8 contacts with Adolfo Herrera?</p> <p>9 MR. BOSTWICK: Same objection.</p> <p>10 THE WITNESS: It was then later in</p> <p>11 1999-2000, I -- The first time I saw Adolfo</p> <p>12 Herrera -- I believe it was in 1998. He -- He</p> <p>13 took part as Mr. Gonzalez's deputy in</p> <p>14 negotiations. And after that, we had contacts</p> <p>15 to --</p> <p>16 THE WITNESS (IN ENGLISH): Finalize.</p> <p>17 THE INTERPRETER: -- finish, finalize</p> <p>18 the negotiations when he was himself manager.</p> <p>19 BY MR. STEWART:</p> <p>20 Q. Did negotiation -- Were negotiations</p> <p>21 over a contract completed when you were there?</p> <p>22 MR. BOSTWICK: Objection. Vague.</p>	<p style="text-align: right;">Page 32</p> <p>1 THE WITNESS: In principle, yeah.</p> <p>2 MR. BOSTWICK: Let's -- Let's -- Let's</p> <p>3 try to do it so that as much is on the record as</p> <p>4 possible.</p> <p>5 MR. STEWART: Right.</p> <p>6 MR. BOSTWICK: Maybe -- I would</p> <p>7 suggest we read back the answer and then you can,</p> <p>8 maybe, ask a direct question for clarification.</p> <p>9 Does that make sense?</p> <p>10 MR. STEWART: Yes. May we have the</p> <p>11 translation of the conversation you just had.</p> <p>12 THE INTERPRETER: Okay. I was</p> <p>13 repeating. I was just asking him if it was -- you</p> <p>14 know, he said yeah. The question was whether --</p> <p>15 whether negotiations completed. And he said there</p> <p>16 was an agreement in principle.</p> <p>17 THE REPORTER: "The negotiations were</p> <p>18 completed. We were agreeing on the principle</p> <p>19 since 1997 but the legal documents have not been</p> <p>20 done until the time of my leaving."</p> <p>21 THE INTERPRETER: Mm-hmm.</p> <p>22 ...</p>

8 (Pages 29 to 32)

<p style="text-align: right;">Page 33</p> <p>1 BY MR. STEWART:</p> <p>2 Q. "Agreeing on the principle." Is it --</p> <p>3 Is it correct to say that there had been an</p> <p>4 agreement reached in principle since 1997?</p> <p>5 A. Yes.</p> <p>6 Q. What were the nature of your</p> <p>7 communications with Jose Luis Monterde?</p> <p>8 A. He gave me a tour of the Zaragoza</p> <p>9 plant.</p> <p>10 Q. Anything else?</p> <p>11 A. No. No.</p> <p>12 Q. Since becoming vice president of</p> <p>13 operations, can you estimate the number of</p> <p>14 communications you had with Clemente Gonzalez</p> <p>15 Azpeitia?</p> <p>16 THE INTERPRETER: What is the name?</p> <p>17 MR. STEWART: It's Clemente Gonzalez</p> <p>18 and there's a last name, Azpeitia.</p> <p>19 THE WITNESS: My contacts with</p> <p>20 Clemente Gonzalez were during meetings for</p> <p>21 negotiations; otherwise, it was Adolfo De Basilio</p> <p>22 who had contact with Clemente Gonzalez. So in</p>	<p style="text-align: right;">Page 35</p> <p>1 conversation with him.</p> <p>2 Q. Did you have written communications</p> <p>3 with Mr. Gonzalez during this time period?</p> <p>4 A. Yes, surely.</p> <p>5 Q. Can you estimate how many?</p> <p>6 MR. BOSTWICK: Objection.</p> <p>7 THE WITNESS: I don't recall. There</p> <p>8 were letters, faxes, letters of quickix (phonetic)</p> <p>9 on the legal negotiation.</p> <p>10 BY MR. STEWART:</p> <p>11 Q. Can you estimate the approximate</p> <p>12 number of written communications you would have</p> <p>13 with Mr. Gonzalez during the course of a month?</p> <p>14 MR. BOSTWICK: Objection. Form.</p> <p>15 THE WITNESS: As much as possible,</p> <p>16 our -- our -- I preferred that written</p> <p>17 communications would happen between Mr. De Basilio</p> <p>18 and Mr. Gonzalez.</p> <p>19 BY MR. STEWART:</p> <p>20 Q. From time to time, you would have</p> <p>21 direct communication with Mr. Gonzalez; is that</p> <p>22 so?</p>
<p style="text-align: right;">Page 34</p> <p>1 all, there were maybe three or four meetings in</p> <p>2 Madrid and two or three in Paris.</p> <p>3 BY MR. STEWART:</p> <p>4 Q. And that was from 19 -- say</p> <p>5 January 1995 until February of 2000?</p> <p>6 A. Yes.</p> <p>7 THE WITNESS (IN ENGLISH): Excuse me.</p> <p>8 No.</p> <p>9 THE INTERPRETER: No. No, because I</p> <p>10 didn't see Mr. Gonzalez after 1999.</p> <p>11 BY MR. STEWART:</p> <p>12 Q. 1995 to 1999?</p> <p>13 A. I believe he was replaced at the</p> <p>14 beginning of 1999 or maybe at the end of 1998. I</p> <p>15 don't remember exactly the date of his</p> <p>16 replacement.</p> <p>17 Q. During that time period, 1995 to 1999,</p> <p>18 did you have telephone conversations with</p> <p>19 Mr. Gonzalez?</p> <p>20 A. I don't recall because Mr. --</p> <p>21 Mr. Gonzalez spoke very little French and I was</p> <p>22 not comfortable enough in Spanish to have a phone</p>	<p style="text-align: right;">Page 36</p> <p>1 A. No, only I -- I remember writing</p> <p>2 letters at critical moments of our cooperation.</p> <p>3 Q. And tell me the number of contacts you</p> <p>4 had with Mr. Herrera.</p> <p>5 A. I had, maybe, two or three meetings</p> <p>6 with Mr. Herrera, maybe four, if you count the one</p> <p>7 in 1998.</p> <p>8 Q. Did you have written communications</p> <p>9 with Mr. Herrera?</p> <p>10 A. I don't recall. I -- I think at</p> <p>11 that -- at that time since we didn't have any more</p> <p>12 disagreements, I didn't need to write to him.</p> <p>13 Q. And what were the nature of your</p> <p>14 communications with Mateo Gasca?</p> <p>15 A. I saw him at the plant. That's all.</p> <p>16 Q. Would you see him at the plant when</p> <p>17 you visited the plant?</p> <p>18 A. Yes.</p> <p>19 Q. Was it your practice to -- I'm sorry.</p> <p>20 Was it your practice to meet Mr. Gasca when you</p> <p>21 visited the Zaragoza plant?</p> <p>22 MR. BOSTWICK: Objection. Form.</p>

9 (Pages 33 to 36)

<p style="text-align: right;">Page 37</p> <p>1 THE WITNESS: Yes. I was there only</p> <p>2 twice to the Zaragoza plant and Mr. Gasca was in</p> <p>3 charge of the manufacturing of the Ethypharm</p> <p>4 product but I didn't -- I didn't have to have</p> <p>5 direct discussions with him.</p> <p>6 BY MR. STEWART:</p> <p>7 Q. And how many -- What was the nature of</p> <p>8 your discussions -- of your contacts with Fernando</p> <p>9 Berenguer?</p> <p>10 A. He took part in negotiations on the</p> <p>11 contract.</p> <p>12 Q. What estimate do you have for the</p> <p>13 number of times you met with Mr. Berenguer?</p> <p>14 A. Two or three times.</p> <p>15 Q. And what was the nature of your</p> <p>16 contacts with Antonio Capodevilla?</p> <p>17 A. None. I don't think I met him.</p> <p>18 Q. Okay. Who did you have contact -- Who</p> <p>19 were the persons at Belmac Corporation, and then</p> <p>20 after the name change, Bentley Pharmaceuticals,</p> <p>21 Incorporated, that you had contact with?</p> <p>22 MR. BOSTWICK: Objection. Timeframe.</p>	<p style="text-align: right;">Page 39</p> <p>1 meetings did not involve the -- did not involve</p> <p>2 directly the business of Ethypharm or of -- of</p> <p>3 Laboratorios Belmac or of Bentley.</p> <p>4 MR. BOSTWICK: Objection. What</p> <p>5 meetings?</p> <p>6 MR. STEWART: The meetings that he</p> <p>7 just mentioned.</p> <p>8 THE WITNESS (IN ENGLISH): Trade</p> <p>9 meeting.</p> <p>10 MR. STEWART: Trade meeting. Okay.</p> <p>11 THE INTERPRETER: Ethypharm business</p> <p>12 had to be involved because everybody was meeting</p> <p>13 their customers and -- and Mr. Murphy, like other</p> <p>14 customers, met with us on the Ethypharm booth but</p> <p>15 we didn't discuss -- What I mean "business," we --</p> <p>16 we didn't negotiate. There was no agenda,</p> <p>17 specific agenda.</p> <p>18 BY MR. STEWART:</p> <p>19 Q. How many trade meetings do you recall</p> <p>20 meeting -- How many trade meetings were there at</p> <p>21 which you met Mr. Murphy?</p> <p>22 A. Ethypharm was going to this meeting I</p>
<p style="text-align: right;">Page 38</p> <p>1 MR. STEWART: From Nineteen Ninety --</p> <p>2 from Dec -- December of 1994 until Mr. Dubois left</p> <p>3 the company in February of 2000.</p> <p>4 THE WITNESS: I met Mr. Murphy with</p> <p>5 whom I had to negotiate. And outside the</p> <p>6 business, in pharmaceutical meetings, I think I</p> <p>7 saw him once or twice with one of his</p> <p>8 collaborators.</p> <p>9 THE WITNESS (IN ENGLISH): Colleague.</p> <p>10 THE INTERPRETER: Colleagues, but I</p> <p>11 don't recall the name of the person.</p> <p>12 BY MR. STEWART:</p> <p>13 Q. What do you mean by "outside the</p> <p>14 business"?</p> <p>15 A. Without having to negotiate anything</p> <p>16 specific, it was in the -- in a -- in a trade</p> <p>17 meeting. It was more of a -- a civil and --</p> <p>18 mundane.</p> <p>19 THE WITNESS (IN ENGLISH): Civil --</p> <p>20 THE INTERPRETER: Yeah.</p> <p>21 BY MR. STEWART:</p> <p>22 Q. So is it fair to say that those</p>	<p style="text-align: right;">Page 40</p> <p>1 mentioned. It was called CPHE -- CPHI and every</p> <p>2 year had a booth there. I think I saw Mr. Murphy</p> <p>3 twice.</p> <p>4 Q. Did you attend the CPHI trade show</p> <p>5 every year?</p> <p>6 A. Yes, but I was not always on the</p> <p>7 Ethypharm booth.</p> <p>8 Q. In addition to the meetings at the two</p> <p>9 trade shows, how many meetings did you have with</p> <p>10 Mr. Murphy?</p> <p>11 MR. BOSTWICK: Objection. Time</p> <p>12 period.</p> <p>13 MR. STEWART: At any time from</p> <p>14 December of 2004 to February of Two Thousand --</p> <p>15 THE INTERPRETER: December.</p> <p>16 MR. STEWART: From December of -- I'm</p> <p>17 sorry. December of 1994 until February of 2000.</p> <p>18 THE WITNESS: I recall two important</p> <p>19 meetings, one in February 1997, the other in April</p> <p>20 '98.</p> <p>21 MR. BOSTWICK: Craig, before you move</p> <p>22 on to this, would it be okay to say that the other</p>

10 (Pages 37 to 40)

<p style="text-align: right;">Page 41</p> <p>1 translator can leave? I mean, I think it's 2 working reasonably well and there's no reason to 3 sit around and incur double costs. Do you -- Do 4 you agree with that? 5 MR. STEWART: I do. 6 MR. BOSTWICK: Okay. 7 MR. STEWART: I do. Thank you. 8 MR. BOSTWICK: I don't -- Thank you. 9 Thank you very much for your help. 10 MR. STEWART: Thank you. 11 BY MR. STEWART: 12 Q. Other than Mr. Murphy, do you 13 recall -- Withdraw that. 14 You mentioned that there was -- that 15 you -- that at one of the trade meetings -- that 16 there was someone with Mr. Murphy that you 17 believed was employed by Bentley; is that correct? 18 A. That's correct. 19 Q. But you don't know the name of that 20 person? 21 A. I think this person introduced himself 22 or herself but I don't remember the name and I</p>	<p style="text-align: right;">Page 43</p> <p>1 to send a letter stating the end of our 2 cooperation with Belmac. 3 Q. Let me -- Why could you not negotiate 4 with Mr. Gonzalez and his team? 5 A. I was negotiating with Mr. Gonzalez 6 and his team but I could not reach an agreement. 7 Q. What were the -- What were the areas 8 of dispute that you had with Mr. Gonzalez and his 9 team? 10 A. Manufacturing costs and compliance 11 with GMP standards or some minor items having to 12 do with sums, amounts that Ethypharm thought being 13 owed to -- 14 THE WITNESS (IN ENGLISH): That 15 Belmac -- 16 THE INTERPRETER: Okay. So Belmac 17 thought that Ethypharm owed them money and 18 Ethypharm didn't want to pay that money but it was 19 minor. 20 BY MR. STEWART: 21 Q. And how long had you been trying to 22 reach an agreement with Mr. Gonzalez?</p>
<p style="text-align: right;">Page 42</p> <p>1 don't remember receiving a card. 2 Q. And other than Mr. Murphy and this 3 other person that -- whose name you cannot 4 remember, did you meet any other people from 5 Bentley Pharmaceuticals? 6 A. No. 7 Q. During the course of your employment 8 as vice president of operations, did you have any 9 contact with any persons at Bentley 10 Pharmaceuticals or Belmac Corporation other than 11 Mr. Murphy? 12 A. No. 13 MR. BOSTWICK: Objection. Form. 14 THE WITNESS (IN ENGLISH): No, no, no, 15 that I can remember. No. 16 THE INTERPRETER: No, I don't recall. 17 MR. STEWART: Okay. 18 BY MR. STEWART: 19 Q. What was the purpose of your meeting 20 with Mr. Murphy in February of 1997? 21 A. Since we couldn't negotiate with 22 Mr. Gonzalez and his team, I asked Mr. De Basilio</p>	<p style="text-align: right;">Page 44</p> <p>1 A. From the end of 1994 until the end of 2 1996. 3 Q. Did you understand at that time that 4 Mr. Gonzalez had authority to negotiate for 5 Laboratorios Belmac? 6 THE INTERPRETER: Gonzalez. Right? 7 MR. STEWART: Yes. 8 THE WITNESS: I thought that in fact 9 as general manager Mr. Gonzalez had the authority 10 to negotiate but since we couldn't reach an 11 agreement I was questioning his ability to 12 negotiate. 13 MR. BOSTWICK: Let me interpose an 14 objection to the translation there. I heard you 15 ask, Craig, about whether he had authority for 16 Laboratorios Belmac and I heard the translation as 17 Belmac Corporation. 18 THE INTERPRETER: Oh, the Laboratorios 19 Belmac. I'm sorry. 20 MR. BOSTWICK: And it was Belmac -- 21 THE INTERPRETER: Oh. 22 MR. BOSTWICK: -- Corporation U.S. so</p>

11 (Pages 41 to 44)

<p style="text-align: right;">Page 45</p> <p>1 I think there's --</p> <p>2 THE INTERPRETER: Oh. Okay.</p> <p>3 MR. BOSTWICK: -- a potential for a</p> <p>4 discrepancy --</p> <p>5 THE INTERPRETER: Okay. Sorry about</p> <p>6 that.</p> <p>7 MR. STEWART: Thank you.</p> <p>8 MR. BOSTWICK: -- because they're</p> <p>9 different entities.</p> <p>10 THE INTERPRETER: Yeah, right.</p> <p>11 MR. BOSTWICK: Perhaps you can maybe</p> <p>12 ask that question again and --</p> <p>13 MR. STEWART: Mm-hmm.</p> <p>14 MR. BOSTWICK: -- and just break it</p> <p>15 out. I just don't want there to be any confusion</p> <p>16 on that point.</p> <p>17 MR. STEWART: Well -- Yeah.</p> <p>18 BY MR. STEWART:</p> <p>19 Q. Did you understand my question to be</p> <p>20 that -- Did you unders -- Did you believe that</p> <p>21 Mr. Gonzalez had authority to negotiate for</p> <p>22 Laboratorios Belmac?</p>	<p style="text-align: right;">Page 47</p> <p>1 contract between Ethypharm Spain and Belmac Spain.</p> <p>2 MR. STEWART: Can we have marked as</p> <p>3 the first exhibit a letter of January 20, 1997.</p> <p>4 (The reporter marked Exhibit 1.)</p> <p>5 THE REPORTER: Dubois 1.</p> <p>6 BY MR. STEWART:</p> <p>7 Q. Mr. Dubois, showing you a document</p> <p>8 that we have marked as Exhibit 1, is that the</p> <p>9 letter that you had Mr. De Basilio send?</p> <p>10 A. Yes.</p> <p>11 Q. What happened after the letter was</p> <p>12 sent?</p> <p>13 A. There were discussions between</p> <p>14 Mr. Gonzalez and Mr. De Basilio and it was</p> <p>15 suggested -- I suppose by Mr. Gonzalez -- that a</p> <p>16 meeting be held with Mr. Murphy.</p> <p>17 Q. If you look at the letter and at the</p> <p>18 second to the -- the -- the second sentence from</p> <p>19 the bottom --</p> <p>20 THE WITNESS (IN ENGLISH): Mm-hmm.</p> <p>21 BY MR. STEWART:</p> <p>22 Q. And you are free to read the Spanish</p>
<p style="text-align: right;">Page 46</p> <p>1 A. Yes.</p> <p>2 Q. Okay.</p> <p>3 And to make sure that we have your</p> <p>4 testimony -- And is it your testimony that --</p> <p>5 that -- that you did believe that Mr. Gonzalez had</p> <p>6 that authority?</p> <p>7 MR. BOSTWICK: Objection. Vague.</p> <p>8 MR. STEWART: It's the same question.</p> <p>9 I -- I was simply trying to -- to make sure that</p> <p>10 we had the -- we had the -- the complete answer.</p> <p>11 THE WITNESS: What I can say is that I</p> <p>12 had to negotiate with him because, apparently, he</p> <p>13 was the proper party but I realize that since the</p> <p>14 situation was stalled, it had to be unstalled at</p> <p>15 another level.</p> <p>16 MR. STEWART: Okay.</p> <p>17 BY MR. STEWART:</p> <p>18 Q. Now, you were saying that you had</p> <p>19 Mr. De Basilio send a letter; is that right?</p> <p>20 A. I believe I recall that, yes.</p> <p>21 Q. And who did --</p> <p>22 A. Since it was about terminating a</p>	<p style="text-align: right;">Page 48</p> <p>1 or the English translation. And my understanding</p> <p>2 from the English translation is that the sentence</p> <p>3 says: We ask you to transmit these decisions to</p> <p>4 your mother company in the United States -- in the</p> <p>5 U.S.</p> <p>6 A. That's correct.</p> <p>7 Q. Can we agree that Mr. De Basilio asked</p> <p>8 Mr. Gonzalez to transmit the matter to the parent</p> <p>9 company in the United States?</p> <p>10 A. No, it was not about trans --</p> <p>11 transmitting matters to the mother company but to</p> <p>12 inform the company of the decisions.</p> <p>13 Q. And the decision was to terminate the</p> <p>14 relationship --</p> <p>15 THE WITNESS (IN ENGLISH): Yes.</p> <p>16 BY MR. STEWART:</p> <p>17 Q. -- unless an agreement could be</p> <p>18 reached?</p> <p>19 A. At the time -- At the time, the</p> <p>20 decision was made to terminate the relationships</p> <p>21 since there was no agreement.</p> <p>22 Q. After the -- After this letter was</p>

12 (Pages 45 to 48)

<p style="text-align: right;">Page 49</p> <p>1 sent, what then occurred?</p> <p>2 A. I think there were exchanges between</p> <p>3 Mr. Gonzalez and Mr. De Basilio as I said. There</p> <p>4 was some kind of agenda of items to be discussed</p> <p>5 and it was suggested to discuss them with</p> <p>6 Mr. Murphy.</p> <p>7 And following this, I met with</p> <p>8 Mr. Murphy in the United States; in Philadelphia,</p> <p>9 if I recall correctly; in the first days of</p> <p>10 February. It was then there was, therefore, very</p> <p>11 quick activity.</p> <p>12 THE WITNESS (IN ENGLISH): A response.</p> <p>13 THE INTERPRETER: A response.</p> <p>14 THE WITNESS: And I believe there was</p> <p>15 a letter from Mr. Murphy following these letters</p> <p>16 to Mr. Debregeas.</p> <p>17 MR. STEWART: Can we have marked as</p> <p>18 the next exhibit a letter dated January 28, 1997</p> <p>19 EP 002450.</p> <p>20 (The reporter marked Exhibit 2.)</p> <p>21 BY MR. STEWART:</p> <p>22 Q. Mr. Dubois, is Exhibit 2 that I have</p>	<p style="text-align: right;">Page 51</p> <p>1 of -- of Belmac Corporation and then Bentley</p> <p>2 Pharmaceuticals.</p> <p>3 Q. Did you speak to Mr. Debregeas --</p> <p>4 to -- to Mr. Debregeas with regard to Mr. Murphy's</p> <p>5 letter to him?</p> <p>6 A. Yes, of course.</p> <p>7 Q. What did Mr. Debregeas -- What did</p> <p>8 Mr. Debregeas say to you?</p> <p>9 A. Or either I told Mr. Debregeas what I</p> <p>10 was going to propose during the meeting.</p> <p>11 Q. What did you -- What did you propose</p> <p>12 to say to Mr. Murphy in the meeting?</p> <p>13 MR. BOSTWICK: Objection. Are we</p> <p>14 talking about what he told Mr. Debregeas he was</p> <p>15 going to propose --</p> <p>16 MR. STEWART: Yes.</p> <p>17 MR. BOSTWICK: -- or what he actually</p> <p>18 proposed at the meeting?</p> <p>19 MR. STEWART: No.</p> <p>20 MR. BOSTWICK: I think the question</p> <p>21 was unclear.</p> <p>22 ...</p>
<p style="text-align: right;">Page 50</p> <p>1 just handed you the letter from Mr. Murphy to</p> <p>2 Mr. Debregeas that you were referring to?</p> <p>3 A. Yes.</p> <p>4 Q. At the time that you wrote the</p> <p>5 letter -- I'm sorry. At the time that it was</p> <p>6 suggested that you meet with Mr. Murphy, did you</p> <p>7 know who Mr. Murphy was?</p> <p>8 THE WITNESS (IN ENGLISH): Of course.</p> <p>9 Yeah. Oui.</p> <p>10 THE INTERPRETER: Yeah. Oui. Yeah.</p> <p>11 Of course, yes.</p> <p>12 BY MR. STEWART:</p> <p>13 Q. And -- And how did you know that?</p> <p>14 A. Because I think there had already been</p> <p>15 frequent contacts between Mr. Murphy and</p> <p>16 Mr. Debregeas because, of course, we knew that</p> <p>17 Belmac Corporation, then Bentley Pharmaceuticals,</p> <p>18 were -- Mr. Murphy at its head.</p> <p>19 Q. Did you also understand that</p> <p>20 Mr. Murphy was president of Laboratorios Belmac?</p> <p>21 A. No, it's possible but I always</p> <p>22 considered Mr. Murphy as the chairman and CEO</p>	<p style="text-align: right;">Page 52</p> <p>1 BY MR. STEWART:</p> <p>2 Q. Is what you told Mr. Debregeas that</p> <p>3 you were going to propose the same as what you</p> <p>4 ultimately told Mr. Murphy?</p> <p>5 A. Of course, there is always some</p> <p>6 exchange before the final propo -- proposition,</p> <p>7 proposal, but since I was scheduled to go several</p> <p>8 days later to see Mr. Murphy, I wanted to make</p> <p>9 sure that Mr. Debregeas agreed with what I was</p> <p>10 going to propose.</p> <p>11 Q. And what did you propose?</p> <p>12 MR. BOSTWICK: Same objection.</p> <p>13 THE WITNESS: I believe I -- I wrote a</p> <p>14 report about this meeting and that all the details</p> <p>15 of my proposal should be in this report.</p> <p>16 BY MR. STEWART:</p> <p>17 Q. We -- We certainly can get to that --</p> <p>18 to that written report later but I'm interested</p> <p>19 now in -- in coming to the meeting with Mr. Murphy</p> <p>20 in Philadelphia.</p> <p>21 A. When I arrived at this meeting, I</p> <p>22 wanted to make sure that Mr. Murphy was</p>

13 (Pages 49 to 52)

<p style="text-align: right;">Page 53</p> <p>1 considering pursuing the relationship with 2 Ethypharm and it's -- his letter to Mr. Debregeas 3 suggested that he wanted an agreement. I then 4 first had to confirm what his intentions were and 5 after that propose a certain number of steps so 6 that Ethypharm would agree with pursuing the 7 meeting. 8 THE WITNESS (IN ENGLISH): I mean the 9 cooperation. 10 THE INTERPRETER: The cooperation. 11 THE WITNESS: We had to settle the 12 items that were still on hold since the 13 discussions with Mr. Gonzalez. 14 MR. BOSTWICK: Can -- 15 THE WITNESS (IN ENGLISH): From the 16 beginning of the discussions. 17 THE WITNESS: From the beginning of 18 discussions with Mr. Gonzalez. 19 MR. BOSTWICK: I'm sorry. I just see 20 a mistake in the translation on the screen. He 21 said "cooperation" and she put "corporation." 22 THE INTERPRETER: Oh, oh.</p>	<p style="text-align: right;">Page 55</p> <p>1 BY MR. STEWART: 2 Q. What did Mr. Murphy respond to this 3 proposal? 4 A. Before this proposal, Mr. Murphy had 5 given me a proposal that was not acceptable but it 6 was in his best interests which was to -- to 7 resume -- 8 THE WITNESS (IN ENGLISH): Not to 9 resume, to take over. 10 THE INTERPRETER: Oh, to take over. 11 Take over for Belmac the manufacturing of the 12 product -- of Ethypharm products in Spain. And my 13 counterproposal seemed acceptable to Mr. Murphy. 14 It was depending, of course, on the realization of 15 the steps that I mentioned whose purpose was not 16 only to prove the feasibility of the cooperation 17 but also Belmac's goodwill. 18 BY MR. STEWART: 19 Q. Where did the meeting take place? 20 A. In Philadelphia in the lobby of a 21 hotel. I don't remember which one. It's the 22 hotels where Mr. Murphy was staying.</p>
<p style="text-align: right;">Page 54</p> <p>1 Cooperation. Okay. 2 MR. BOSTWICK: I believe the 3 translator said cooperation. Is that your memory? 4 MR. STEWART: It is. 5 Let's go off the record for a minute. 6 THE VIDEOGRAPHER: The time is 7 11:31:03. Off the record. 8 (Discussion off the record.) 9 THE VIDEOGRAPHER: On the record. The 10 time is 11:33:24. 11 THE WITNESS (IN ENGLISH): Shall I 12 continue my response? 13 MR. STEWART: Yes, please. 14 THE WITNESS: -- for these texts were 15 to enable the resolution of the items that were on 16 hold since the beginning of the negotiations with 17 Mr. Gonzalez, resume manufacturing of Omeprazole 18 at -- in economical conditions, acceptable 19 conditions for Ethypharm, set up the GMP 20 procedures for which Belmac was deficient, and in 21 return, of course, settle the issue of the amounts 22 owed by -- by Ethypharm.</p>	<p style="text-align: right;">Page 56</p> <p>1 Q. You mentioned that as part of the 2 proposal that there was to be GMP procedures put 3 in place in which -- as to which Belmac was 4 deficient; is that right? 5 A. That's correct. 6 Q. And you mentioned earlier that -- that 7 you ordered two audits conducted of the Bel -- 8 Laboratorios Belmac facilities; is that right? 9 A. That's correct. 10 Q. Did those audits occur before the 11 meeting with Mr. Murphy? 12 A. The first one, yes. 13 Q. And was Mr. Murphy, to your knowledge, 14 aware that that audit had occurred? 15 A. He pretended not to be and the audit 16 report was sent to him upon my return to Paris. 17 Q. When you say, "he pretended," you mean 18 he was -- 19 THE WITNESS (IN ENGLISH): He said. 20 MR. STEWART: I'm sorry? 21 THE INTERPRETER: He said. 22 MR. STEWART: Okay.</p>

14 (Pages 53 to 56)

<p style="text-align: right;">Page 57</p> <p>1 BY MR. STEWART:</p> <p>2 Q. In English, for a person to pretend</p> <p>3 means that he -- he knew something but acted in a</p> <p>4 different way. Is that what you meant?</p> <p>5 A. No, because I cannot judge what he</p> <p>6 knew and what he didn't know.</p> <p>7 Q. So he said that he was not aware of</p> <p>8 that audit; is that right?</p> <p>9 A. That's correct.</p> <p>10 Q. He didn't -- He wasn't present for the</p> <p>11 audit, was he?</p> <p>12 A. Of course not.</p> <p>13 Q. There were employees of Laboratorios</p> <p>14 Belmac who were present for the audit; correct?</p> <p>15 A. Of course. It was an audit of the</p> <p>16 employees as well as the plant of Labora -- of</p> <p>17 Belmac laboratories.</p> <p>18 Q. Do you remember who those employees</p> <p>19 were who were present at the audit?</p> <p>20 A. I was not myself presence -- present</p> <p>21 or joined the audit. This audit was performed on</p> <p>22 one of the -- Mrs. Gavaille's colleagues.</p>	<p style="text-align: right;">Page 59</p> <p>1 the Belmac Spain team. Well, many exchanges</p> <p>2 between Mr. De Basilio and the team of Belmac</p> <p>3 Spain and a meeting that happened in April with</p> <p>4 the people from Belmac.</p> <p>5 Q. A meeting in April of 1997?</p> <p>6 A. Yes. Yeah.</p> <p>7 Q. Who was at that meeting?</p> <p>8 A. Mr. Murphy was to come to this meeting</p> <p>9 but at the last minute, he couldn't come, and</p> <p>10 there was, I think, Clemente Gonzalez, probably</p> <p>11 Berenguer, then perhaps another person or -- or</p> <p>12 two from Belmac. And on our side, of course,</p> <p>13 myself and Adolfo De Basilio and the Ethypharm --</p> <p>14 Ethypharm team.</p> <p>15 Q. What occurred at that meeting?</p> <p>16 A. I remember that we had to clarify</p> <p>17 again what I had told Mr. Murphy but that there</p> <p>18 was during this meeting a certain delay observed</p> <p>19 in the realization of the scheduled steps -- or,</p> <p>20 rather, under time table for the realization of</p> <p>21 the scheduled steps.</p> <p>22 Q. Was this -- I -- I don't -- I don't --</p>
<p style="text-align: right;">Page 58</p> <p>1 Mrs. Gavaille is responsible or in charge of the</p> <p>2 quality at Ethypharm. And as -- And I assume that</p> <p>3 an audit and report must exist -- reviewed all the</p> <p>4 procedures concerning manufacturing of the</p> <p>5 Ethypharm products. I remember sending myself</p> <p>6 upon my return a letter to Mr. Murphy with a copy</p> <p>7 of the report.</p> <p>8 MR. STEWART: Let me have marked,</p> <p>9 please, as the next exhibit a fax front page dated</p> <p>10 February 14th, 1997 with the following letter from</p> <p>11 Mr. Dubois and a -- a document titled Audit of the</p> <p>12 Ethypharm Production Site in Zaragoza.</p> <p>13 (The reporter marked Exhibit 3.)</p> <p>14 BY MR. STEWART:</p> <p>15 Q. Mr. Dubois, is the letter -- is the</p> <p>16 fax cover sheet, the letter, and the audit that</p> <p>17 we've marked as Exhibit 3 the document that you</p> <p>18 were referring to in your testimony?</p> <p>19 A. That's correct. That's it.</p> <p>20 Q. After you sent the letter to</p> <p>21 Mr. Murphy, what happened? What happened next?</p> <p>22 A. There were exchanges and meetings with</p>	<p style="text-align: right;">Page 60</p> <p>1 I don't understand the delay in the scheduled</p> <p>2 steps.</p> <p>3 A. One of the critical points was the</p> <p>4 manufacturing of 20 lots of Omeprazole.</p> <p>5 THE WITNESS (IN ENGLISH): Before</p> <p>6 the -- the end of the summer.</p> <p>7 THE INTERPRETER: Before the end of</p> <p>8 the summer.</p> <p>9 And we realized in April that it could</p> <p>10 not be the case.</p> <p>11 BY MR. STEWART:</p> <p>12 Q. You realized that as a result of</p> <p>13 discussions with the Belmac people?</p> <p>14 A. Yes, but I -- I think there were</p> <p>15 exchanges already between the Clemente Gonzalez</p> <p>16 and Adolfo De Basilio that indicated that.</p> <p>17 Q. Please continue with -- My question</p> <p>18 was what happened at the -- at the April 1997</p> <p>19 meeting.</p> <p>20 A. What I told you, there were delays and</p> <p>21 Ethypharm's accepted these delays as form of</p> <p>22 goodwill going towards what we wanted in the hope</p>

15 (Pages 57 to 60)

<p style="text-align: right;">Page 61</p> <p>1 that we would reach a solution based on what had 2 been discussed with Mr. Murphy. 3 Q. And was a solution reached? 4 A. I remember that in September we made a 5 proposal for an agreement. I think it was 6 September. I don't recall. And that the -- the 7 complete proposal included even a price for the 8 manufacturing of the product. And, of course, the 9 reimbursement of the amounts due. We had at that 10 time the feeling that Belmac could manage to 11 manufacture the required lot -- number of lots of 12 Omeprazole. And we had indications that the GMP 13 rules were beginning to be put in place. And I 14 think that there was a GMP audit that was 15 performed at the end of the year. 16 Q. That would be the end of 1997? 17 A. Yes, I believe. 18 Q. Who was present at that audit? 19 A. Not me. It was performed by Marcelle 20 Gavaille herself, I believe, of the Zaragoza plant 21 with all the people from the plant. And, 22 probably, maybe Mr. De Basilio had to be present.</p>	<p style="text-align: right;">Page 63</p> <p>1 is a -- This is a good time. I'll be moving on to 2 a couple other things so this is a good time to 3 stop. 4 MR. BOSTWICK: Okay. 5 THE VIDEOGRAPHER: This ends Tape No. 6 1 of the Dubois deposition. The time is 11:50:25. 7 Off the record. 8 (Recess.) 9 THE VIDEOGRAPHER: On the record with 10 Tape No. 2 of the testimony of Claude Dubois in 11 the matter of Ethypharm versus Bentley 12 Pharmaceuticals. The date is July 12th, 2006. 13 The time is 12:17 -- Oh, well -- 01. 14 MR. STEWART: Mr. Dubois, I'm going to 15 show you two -- two draft agreements. And first I 16 want to have our stenographer mark as the next 17 exhibits a document that begins with the Bates 18 number 9082 -- EP 009082 with a cover sheet from a 19 Javier Santos and as the next -- as the exhibit 20 following -- I believe it would be Exhibit 5 -- a 21 document that begins with an Ethypharm Bates 22 number, 009008.</p>
<p style="text-align: right;">Page 62</p> <p>1 Q. Was Mr. Murphy present? 2 A. Neither Mr. Murphy nor Mr. Gonzalez. 3 An audit is not performed in the presence of the 4 managers. 5 THE WITNESS (IN ENGLISH): General 6 manager. 7 THE WITNESS: General manager. 8 BY MR. STEWART: 9 Q. Is that by rule or just by 10 convenience? 11 A. The general management doesn't have to 12 be audited for -- for such an audit which has to 13 do only with the procedures and manufacturing 14 criteria. 15 MR. BOSTWICK: Craig, we've been going 16 about an hour and a half, two hours. Will you -- 17 Do you have a -- I mean -- I don't mean to -- If 18 you -- If you're -- 19 MR. STEWART: No. This is -- 20 MR. BOSTWICK: -- at a section and you 21 could -- 22 MR. STEWART: No, no, this is -- this</p>	<p style="text-align: right;">Page 64</p> <p>1 (The reporter marked Exhibit 4.) 2 (The reporter marked Exhibit 5.) 3 BY MR. STEWART: 4 Q. Mr. Dubois, I -- I don't intend to ask 5 you questions in detail on either Exhibit 4 or 6 Exhibit 5. 7 THE WITNESS (IN ENGLISH): Okay. 8 BY MR. STEWART: 9 Q. So I would propose that I put to you 10 my question and then take whatever time you need 11 to review the document if you -- if you feel 12 that's necessary. Is that agreeable? 13 A. Yes. 14 Q. Referring to Exhibit -- what we have 15 marked as Exhibit 4, have you seen the Draft 14 16 March 1995 Memorandum of Understanding before 17 today? 18 (Discussion off the record.) 19 THE WITNESS: I'm looking. 20 There were many drafts of our agreements 21 that were exchanged. I don't recall 22 specifically -- specifically this one. I think</p>

16 (Pages 61 to 64)

<p style="text-align: right;">Page 65</p> <p>1 this one is a draft that were -- that was written 2 by Spanish attorneys on the instructions by Adolfo 3 De Basilio. 4 BY MR. STEWART: 5 Q. Would you look at Exhibit 5, please. 6 And have you seen the document that is titled 7 "Agreement" which -- 8 A. Yeah. This document seems familiar to 9 me. In fact, it is dated July, and that's what I 10 thought was sent in September. 11 Q. Who prepared the original -- Who 12 prepared the typewritten portion of this document? 13 A. I think it -- I think it is Ethy -- 14 Ethypharm Spain. 15 Q. Was this document done under your 16 direction? 17 A. Yes, probably. Yes. 18 Q. And let me direct your attention to 19 the parties to the agreement. The first party is 20 Ethypharm S.A. Spain; is that correct? 21 A. Yes. 22 Q. And Ethypharm Spain is represented by</p>	<p style="text-align: right;">Page 67</p> <p>1 think so. 2 BY MR. STEWART: 3 Q. At some point did you understand that 4 Mr. Murphy was the executive director of 5 Laboratorios Belmac? 6 A. I just realized that I thought it was 7 the document that was sent in 1997 but it was sent 8 in 1995. And I don't recall these documents. 9 Q. In 19 -- In July of 1995, you were 10 vice president of operations of Ethypharm France; 11 is that correct? 12 A. That's correct. 13 Q. And matters of contract were under 14 your jurisdiction; is that right? 15 A. That's correct. 16 Q. Is it probable that this document came 17 to your attention in July of 1995? 18 A. It's probable. 19 MR. STEWART: Now I would like to turn 20 to September of 1997. And I'd like to have marked 21 as the next exhibit a letter of 3 September 1997 22 to Mr. Dubois.</p>
<p style="text-align: right;">Page 66</p> <p>1 its president, Mr. Patrice Debregeas; correct? 2 A. Yes, that's what's written. 3 Q. Yes. And the second party is 4 Laboratorios Belmac S.A.? 5 A. Yes. 6 Q. Is that -- And is that correct? Okay. 7 A. Yes. 8 Q. And it is represented by, according to 9 the agreement, its executive director, Mr. James 10 R. Murphy. 11 A. Yes. Again, that's what's written. 12 Q. When was the first time that you 13 understood that Mr. Murphy was the executive 14 director of Laboratorios Belmac S.A.? 15 MR. BOSTWICK: Objection. Foundation 16 and the form of the question's -- assumes a fact 17 not in evidence. 18 MR. STEWART: Well, let me see if I 19 can clear that up a little bit. 20 MR. BOSTWICK: It's a 21 when-did-you-beat-your-wife. 22 MR. STEWART: At some -- No, I don't</p>	<p style="text-align: right;">Page 68</p> <p>1 (The reporter marked Exhibit 6.) 2 BY MR. STEWART: 3 Q. Mr. Dubois, do you recognize Exhibit 6 4 as a letter that was sent to you by Mr. Clemente 5 Gonzalez in September of 1997? 6 A. Yes. 7 Q. You mentioned earlier in the morning 8 that in September there were -- I believe you said 9 progress toward agreement including agreement on 10 price. Do I under -- Do I understand that -- Have 11 I understood that testimony correctly? 12 A. I don't remember seeing this. 13 Q. Right. 14 A. I remember seeing that following my 15 meeting with Mr. Murphy in February. We were in 16 agreement on the procedure to get out of the 17 stalling -- and that during our meeting in April 18 with Mr. Gonzalez and his team -- 19 THE WITNESS (IN ENGLISH): We still 20 were -- 21 THE INTERPRETER: We still had delays 22 in our progress. Our progress was still delayed.</p>

17 (Pages 65 to 68)

<p style="text-align: right;">Page 69</p> <p>1 And that in September we sent a -- a -- a draft 2 agreement, probably following this letter, from 3 Mr. Gonzalez. So it was -- it was September in my 4 memory, my recollection, and not July, since the 5 document that you showed previously -- 6 THE WITNESS (IN ENGLISH): Were in 7 fact July 1995. 8 THE INTERPRETER: Were July 95. 9 MR. STEWART: Right. 10 BY MR. STEWART: 11 Q. Who -- Who was involved in the 12 drafting of the agreement that was sent in 13 September of 1997? 14 MR. BOSTWICK: I'm just going to 15 object. We don't have it. 16 THE WITNESS: I would have -- have to 17 review this draft but in theory would have been 18 the legal department of Ethypharm with -- 19 MR. STEWART: Okay -- 20 THE WITNESS: -- with instructions 21 from Adolfo De Basilio and myself. 22 ...</p>	<p style="text-align: right;">Page 71</p> <p>1 start with Belmac -- Belmac Bates number 006381. 2 (The reporter marked Exhibit 7.) 3 THE REPORTER: Whoops. 4 MR. STEWART: And Belmac Exhibit 8 5 starts with Belmac Bates number 006372. 6 (The reporter marked Exhibit 8.) 7 MR. STEWART: And Exhibit 8 is Belmac 8 006371. 9 MR. BOSTWICK: No. 10 THE REPORTER: Nine. 11 MR. BOSTWICK: I think you just marked 12 two No. 8 so -- 13 MR. STEWART: Oh, I -- I beg your 14 pardon. I'm sorry. No. 9. 15 MR. BOSTWICK: So this next one -- 16 this next one -- 17 MR. STEWART: I misspoke. Exhibit 9 18 has as -- 006371 as its first page. 19 (The reporter marked Exhibit 9.) 20 BY MR. STEWART: 21 Q. Mr. Dubois, let me know when you've 22 had a chance to look through those documents.</p>
<p style="text-align: right;">Page 70</p> <p>1 BY MR. STEWART: 2 Q. Who was in the legal department at 3 that time? 4 A. Mrs. Joannesse. 5 Q. Was Madame Joannesse a lawyer? 6 A. Not -- Not -- Not a lawyer but a -- 7 Hmm. JD. Yeah. That's -- That's -- In English I 8 think that's the -- She didn't have -- She didn't 9 pass the bar. She didn't have the bar. She 10 didn't pass the bar exam but she was -- she had a 11 law degree. 12 MR. STEWART: Is that what he said? 13 THE INTERPRETER: Yeah. 14 THE WITNESS (IN ENGLISH): Jurist. 15 THE INTERPRETER: Jurist. 16 (Mr. Stewart conferred with 17 Mr. Mingolla.) 18 MR. STEWART: I'd like to mark as the 19 next three exhibits what I have -- what I believe 20 to be three drafts of the same typewritten 21 agreement, one of which contains -- is a facing 22 page notes. And so Exhibit 7 will be -- will</p>	<p style="text-align: right;">Page 72</p> <p>1 A. All right. I'm done. 2 Q. Do you recognize either Exhibit 7, 3 Exhibit 8, or Exhibit -- Exhibit 9? 4 A. I recognize Exhibit 9. I believe it 5 was the draft contract that was sent by Ethypharm 6 Spain to Belmac Spain at the beginning of 7 September. This is the contract I was referring 8 to earlier in my testimony. 9 MR. STEWART: May I have Mr. Dubois' 10 answer back, please. 11 THE REPORTER: "I recognize Exhibit 9. 12 I believe it was the draft contract that was sent 13 by Ethypharm Spain to Belmac Spain at the 14 beginning of September. This is the contract I 15 was referring to earlier in my testimony." 16 BY MR. STEWART: 17 Q. And what involvement, if any, did you 18 have with respect to Exhibit 9? 19 A. So Exhibit 9 is the contract plus 20 comments which I believe came from Belmac and that 21 I was not aware of. Exhibits 7 and 8 are the same 22 contract as far as I can judge with the changes</p>

18 (Pages 69 to 72)

<p style="text-align: right;">Page 73</p> <p>1 and I don't know if they came before or after the 2 changes that are mentioned on Exhibit 9. 3 Q. Where was the -- Where was Exhibit -- 4 Where was the contract which is part of Exhibit 9 5 drafted? 6 A. I think it was drafted by Ethypharm 7 Spain since it is a Spanish -- it is in Spanish -- 8 that it was done from a draft made by 9 Mrs. Joannesse. 10 Q. Was that draft -- Was the -- Was the 11 draft done in consultation with you? 12 A. This draft was made in consultation 13 with me even in its Spanish form. 14 Q. Do you recognize the handwriting on 15 Exhibit 9 that is on the page that has the number 16 006371? 17 A. No. 18 Q. Do you recognize any of the 19 handwriting on Exhibit 9 from pages 6389 to the 20 end of the document? 21 A. Seems -- There seem to be handwriting 22 from different authors and based on the place</p>	<p style="text-align: right;">Page 75</p> <p>1 THE INTERPRETER: My assumption. 2 THE WITNESS (IN ENGLISH): My 3 assumption. 4 5 THE INTERPRETER: Mm-hmm. My 6 assumption is that the first document is the one 7 that has the -- the word "Borrador, 3/09/97," 8 because "borrador" in Spanish means draft -- and 9 that this indication has disappeared from the 10 other documents. 11 MR. STEWART: Mm-hmm. Furthermore, 12 this contract was the one that was sent by fax on 13 September 14th from Ethypharm. 14 THE WITNESS (IN ENGLISH): Probably to 15 Belmac Spain. 16 THE INTERPRETER: Probably to Belmac 17 Spain. 18 BY MR. STEWART: 19 Q. Is it your belief, Mr. Dubois, that 20 what we have marked as Exhibit 9 -- the first 21 draft of this contract? 22 A. That's what I just said, except, of</p>
<p style="text-align: right;">Page 74</p> <p>1 where they are, I think these are mentions by 2 Belmac. 3 MR. STEWART: These are what? 4 THE INTERPRETER: These are comments. 5 MR. STEWART: Comments. 6 THE INTERPRETER: Comments by Belmac. 7 MR. BOSTWICK: I'm going to interpose 8 an objection having had an opportunity to review 9 7, 8, and 9 simply because it appears that this is 10 not the order in which these were produced from 11 the files of Belmac. I -- I see on Exhibit 9, 12 it's -- 6371 is the Bates number and then the next 13 Bates number is 6389. And to the extent we're 14 purporting to say that these are the same or part 15 of one document -- I would need some form of 16 representation on that. If anything, it looks 17 like the first page, 6371, was attached to 18 Exhibit 8, not Exhibit 9. But I'll stop there. 19 THE WITNESS: That's what I said in my 20 testimony, that I didn't know if Exhibit 7 and 8 21 came before or after Exhibit 9. 22</p>	<p style="text-align: right;">Page 76</p> <p>1 course, the cover page -- 2 Q. Yeah. 3 A. -- the facing page. 4 Q. And which in your -- in your view, is 5 the second draft -- Do you have any -- any -- any 6 view with regard to that point? 7 A. I have no idea. I didn't see the 8 other draft, I think. 9 Q. So you have a recollection of seeing 10 Exhibit 9; is that right? 11 MR. BOSTWICK: Object. 12 THE WITNESS: Except for the facing 13 page. 14 BY MR. STEWART: 15 Q. Okay. But you have no recollection of 16 seeing the drafts that are -- we've identified as 17 Exhibit 7 and Exhibit 8; is that right? 18 A. That is correct but I must -- I must 19 also add that in the exhibit that you have marked, 20 the document that you have marked, as Exhibit 9, I 21 haven't seen the document with the handwritten 22 comments.</p>

19 (Pages 73 to 76)

<p style="text-align: right;">Page 77</p> <p>1 Q. Briefly, if you would turn to 2 Exhibit 7. Do you recognize the handwriting in 3 Exhibit 7? 4 A. No. 5 Q. And turn to Exhibit 8, please. Do you 6 recognize the handwriting in Exhibit 8? 7 THE WITNESS (IN ENGLISH): Not really. 8 THE INTERPRETER: No, not either. 9 BY MR. STEWART: 10 Q. Turning to Exhibit 9 -- 11 A. I must say that all these comments are 12 in Spanish. Nobody at the Ethypharm headquarters 13 would have made comments in Spanish. 14 Q. Okay. 15 A. And these comments in Spanish probably 16 come from somebody at Belmac or at Ethypharm Spain 17 and I'm not familiar with anybody's handwriting at 18 Ethypharm Spain. They never wrote to me in 19 handwriting -- in handwritten form and in Spanish. 20 Q. My questions now will only concern the 21 typewritten portion of the draft contract. 22 MR. BOSTWICK: On Exhibit 9?</p>	<p style="text-align: right;">Page 79</p> <p>1 2 THE INTERPRETER: No. 3 MR. BOSTWICK: Objection to form. 4 BY MR. STEWART: 5 Q. If you had so desired -- could you 6 have added Bentley Pharmaceuticals, Incorporated, 7 as one party -- as an additional party and 8 Ethypharm S.A. France as an additional party? 9 A. Again, this is a legal document 10 between the Spanish companies for which neither 11 Ethypharm France and Bentley Pharmaceutical, even 12 though everything is made under their decisions, 13 cannot be parties. 14 Correction of what I said. 15 THE WITNESS (IN ENGLISH): If I -- If 16 I had the desire -- 17 18 THE INTERPRETER: The answer was, even 19 if we had the desire, the will, to -- to be part 20 of this contract, legally, we could not be part of 21 this contract. 22 And even if it was the -- a decision to</p>
<p style="text-align: right;">Page 78</p> <p>1 MR. STEWART: On Exhibit 9, yes. 2 THE WITNESS: Understood. 3 BY MR. STEWART: 4 Q. Who was the -- Who was the draft 5 contract that we've marked as Exhibit 9 between? 6 A. It could only be between Ethypharm 7 Spain and Belmac Laboratories, Spain since 8 Ethypharm Spain was the order giver, manufacturing 9 order giver, and the -- Laboratories Belmac Spain 10 was the contract manufacturer. 11 Q. When you say it could only be between 12 Laboratorios Belmac Spain and Ethypharm S.A. 13 Spain, what is the reason that it could only be 14 between those two companies? 15 A. For the reasons I just gave. It's a 16 legal document so it's a contract between the 17 Spanish companies on the Spanish territory. 18 Q. Are you aware of any contracts between 19 Ethypharm France and Bentley Pharmaceuticals, 20 Incorporated, which duplicate the terms that are 21 in Exhibit 9? 22 THE WITNESS (IN ENGLISH): No.</p>	<p style="text-align: right;">Page 80</p> <p>1 get into the contract was made by Ethypharm France 2 and Bentley Pharmaceutical, the legal documents 3 had to be made between Spanish companies. 4 BY MR. STEWART: 5 Q. If you so desired, was there anything 6 to prevent you from having a separate agreement 7 between Bentley Pharmaceuticals and Ethypharm 8 France if that was your intention? 9 A. I don't really understand the 10 question. I don't think this is about contract 11 manufacturing. I think this concerns other 12 cooperations. And in this case, it was possible 13 but for things that do not concern Spain. 14 Correction. Manufacturing in Spain. 15 Q. Mm-hmm. If the obligation for payment 16 between -- If -- If you wanted the obligation of 17 payment to be between Bentley Pharmaceuticals, 18 Incorporated, and Ethypharm France, could there 19 have been a document created which would express 20 that? 21 MR. BOSTWICK: Objection. Objection. 22 Calls for a legal conclusion and speculation.</p>

20 (Pages 77 to 80)

<p style="text-align: right;">Page 81</p> <p>1 THE WITNESS: I do not understand 2 which payment obligation is referred to. 3 MR. STEWART: Okay. The obligation 4 of, for example, Ethypharm to pay Bentley 5 Pharmaceuticals, Inc., for the product which 6 Laboratorios Belmac would supply. 7 MR. BOSTWICK: Same objection. 8 THE WITNESS: This seems perfectly 9 illegal to me. 10 MR. STEWART: Perfectly? 11 THE WITNESS: Illegal -- 12 MR. STEWART: Illegal. 13 THE WITNESS: -- to me -- because 14 Belmac performs some work for Ethypharm Spain. 15 And I don't see why it would be Ethypharm Spain, 16 and even more, Ethypharm France that would pay the 17 mother company of Belmac for work performed in 18 Spain by its Spanish subsidiary. 19 MR. STEWART: Okay. 20 BY MR. STEWART: 21 Q. Did you ever contemplate a contract 22 between Ethypharm Spain, Ethypharm France, and</p>	<p style="text-align: right;">Page 83</p> <p>1 BY MR. STEWART: 2 Q. Did -- Did Mr. -- Did Jim Murphy, to 3 your knowledge, make any comments or changes to 4 the -- to Exhibit 9? 5 MR. BOSTWICK: Objection. Objection 6 to the Exhibit 9 and he has said he never saw it 7 in this form. 8 MR. STEWART: Let me -- Let me -- Let 9 me make clear. When I'm referring to -- I'll -- 10 I'll refer to the typewritten portion of the draft 11 contract as part of Exhibit 9. 12 THE WITNESS: I don't remember having 13 received any comments, either from Ethypharm or 14 from Bentley Pharmaceuticals; in other words -- 15 Belmac, Belmac or Ethypharm. 16 THE WITNESS (IN ENGLISH): No, Belmac 17 or Bentley. 18 THE INTERPRETER: Bentley. I'm sorry. 19 Belmac or Bentley. In other words -- So I never 20 received any comments on this draft contract which 21 was not followed by official changes. 22 . . .</p>
<p style="text-align: right;">Page 82</p> <p>1 Ethypharm -- and -- Sorry -- Ethypharm France and 2 Bentley Pharmaceuticals to guarantee that 3 Laboratorios Belmac would keep its obligations to 4 Ethypharm Spain? 5 MR. BOSTWICK: Can we clarify whether 6 that's written or oral? 7 MR. STEWART: Either one. 8 THE WITNESS: Written confirmation 9 doesn't seem to have any legal value since, again, 10 it's between two Spanish companies contracting for 11 work done in Spain; but, of course, Ethypharm -- 12 or Ethypharm wanted to make sure that Bentley was 13 in agreement for its subsidiary to get into this 14 contract and that is even how we unstalled the 15 situation. 16 MR. STEWART: How we? 17 THE WITNESS: How we got the situation 18 out of stalling. 19 THE WITNESS (In English): Unblock. 20 THE INTERPRETER: Unblock, yeah. 21 MR. STEWART: Okay. 22 . . .</p>	<p style="text-align: right;">Page 84</p> <p>1 BY MR. STEWART: 2 Q. Did -- Do you know whether Mr. Murphy 3 directed anyone at Laboratorios Belmac to make 4 changes to the written -- to the typewritten 5 portion of Exhibit 9? 6 MR. BOSTWICK: Objection. Form. 7 THE WITNESS: I have no way to know 8 that. 9 BY MR. STEWART: 10 Q. Are you aware of any employee at 11 Bentley Pharmaceuticals that had any involvement 12 in making comments to the draft typewritten 13 contract that is part of Exhibit 9? 14 MR. BOSTWICK: Same objection. Form, 15 and the -- to the exhibit. 16 THE WITNESS: Same answer for me. I 17 have no way to know that. 18 MR. STEWART: Okay. 19 BY MR. STEWART: 20 Q. After the exchange -- After -- Let me 21 withdraw that. 22 Describe, please, what happened</p>

21 (Pages 81 to 84)

<p style="text-align: right;">Page 85</p> <p>1 following the draft of the contract which is part 2 of Exhibit 9; that is, following the receipt by 3 Laboratorios Belmac of the draft of Exhibi -- the 4 draft contract that's part of Exhibit 9. 5 MR. BOSTWICK: Objection to the form 6 of the question. It's also vague. And to 7 Exhibit 9. 8 THE WITNESS: Okay. And I did not 9 receive any comments on the draft contract as it 10 is in the typewritten portion in Exhibit 9. 11 BY MR. STEWART: 12 Q. Okay. What occurred with respect to 13 contract negotiations between Laboratorios Belmac 14 and Ethypharm Spain? 15 MR. BOSTWICK: Objection. Vague. 16 Timeframe. 17 MR. STEWART: Timeframe -- 18 MR. BOSTWICK: And -- 19 MR. STEWART: The timeframe -- The 20 timeframe following the receipt of the contract 21 that is part of Exhibit 9 and continuing -- and 22 continuing through February of 2000.</p>	<p style="text-align: right;">Page 87</p> <p>1 MR. STEWART: That's fine. 2 MR. BOSTWICK: Is that acceptable? 3 THE WITNESS: So now I can answer the 4 question as I understand it? We did not get -- We 5 did not receive feedback on this proposal. The 6 work continued at Belmac Spain. Based on what we 7 had agreed upon -- Based on what was agreed upon 8 after the meeting with Mr. Murphy and the letter 9 from Mr. Gonzalez dated September, we performed a 10 new quality audit and we worked with the other -- 11 through other meetings towards the writing of this 12 contract. A meeting occurred in April 1998 and -- 13 and we resolved a number of important items 14 through separate agreements concerning compliance 15 with confidentiality by Belmac -- and their 16 recognition of the ownership of no-how and 17 technology of Ethypharm by Belmac but no contract 18 settling the issue of manufacturing was done 19 before the beginning of 2000. 20 BY MR. STEWART: 21 Q. Okay. First, you say you did not 22 receive any feedback on this proposal. By "this</p>
<p style="text-align: right;">Page 86</p> <p>1 MR. BOSTWICK: Same objection with the 2 exhibit objection. 3 THE WITNESS: Pardon? 4 MR. BOSTWICK: The same objection with 5 the objection to the exhibit. 6 THE WITNESS: It's a typewritten 7 exhibit that we're talking about. 8 BY MR. STEWART: 9 Q. Yeah, just so we don't -- we don't 10 have to continue to have Mr. Bostwick have to 11 object, when I'm asking you with respect to the 12 draft contract dated September of 1997, I am 13 referring only to the typewritten portion of that 14 contract and I am not referring to the handwritten 15 notes that are part of Exhibit 9. Do you 16 understand? 17 A. Understood. 18 MR. STEWART: Okay. 19 MR. BOSTWICK: And -- And if it's 20 okay, I'll just maintain those objections for your 21 next series of questions with respect to Exhibit 9 22 and then I won't have to interrupt you.</p>	<p style="text-align: right;">Page 88</p> <p>1 proposal," do you mean the typewritten contract 2 dated March 9, 1997? 3 THE INTERPRETER: It's September 3rd. 4 5 THE WITNESS (In English): September 6 3rd. 7 MR. STEWART: I'm sorry. I beg your 8 pardon -- September 3, 1997 which is part of 9 Exhibit 9. 10 THE INTERPRETER: Yes. 11 BY MR. STEWART: 12 Q. And yet there appears to be a great 13 deal of feedback in the form of notes. 14 A. It is not customary to -- to give as 15 feedback a copy of the document with handwritten 16 notes but, rather, to create a new draft, a new 17 written draft, and I don't know who this -- these 18 copies with handwritten notes were transmitted to. 19 And there was never any meeting to discuss 20 suggestions of changes to this contract. 21 THE WITNESS (IN ENGLISH): To the best 22 of my knowledge.</p>

22 (Pages 85 to 88)

<p style="text-align: right;">Page 89</p> <p>1 MR. STEWART: Okay.</p> <p>2 BY MR. STEWART:</p> <p>3 Q. And you stated that a meeting</p> <p>4 occurred -- Now, let me withdraw that.</p> <p>5 You stated that "we" performed a new</p> <p>6 audit --</p> <p>7 A. I seem to recall that the new audit,</p> <p>8 like the previous one, was performed by Marcelle</p> <p>9 Gavaille to confirm that GMP procedures were being</p> <p>10 put in place because based on the letter from</p> <p>11 Mr. Gonzalez dated September 3rd which indicated</p> <p>12 that the quality assurance experts had performed</p> <p>13 an audit, we had to confirm that it was the case</p> <p>14 and that it was being put in place.</p> <p>15 Q. And that audit was formed by Ethypharm</p> <p>16 France?</p> <p>17 A. Yes, as always.</p> <p>18 Q. Was Mr. Murphy involved in any way</p> <p>19 with that audit?</p> <p>20 A. Like I said previously, general</p> <p>21 managers, whether it be Mr. Murphy, Mr. Gonzalez,</p> <p>22 Mr. Debregeas, or myself are never present for an</p>	<p style="text-align: right;">Page 91</p> <p>1 THE WITNESS (IN ENGLISH): We had put</p> <p>2 something in writing.</p> <p>3 THE INTERPRETER: We had put,</p> <p>4 ourselves, something in writing.</p> <p>5 MR. STEWART: I don't understand what</p> <p>6 you mean, then, that there was no juridica --</p> <p>7 no -- no -- no juridita -- no juridifical.</p> <p>8 THE WITNESS: Legal transcription.</p> <p>9 MR. STEWART: No legal transcription.</p> <p>10 BY MR. STEWART:</p> <p>11 Q. What do you mean by "legal</p> <p>12 transcription"?</p> <p>13 A. A duly written agreement signed by</p> <p>14 both parties.</p> <p>15 Q. And it was your -- It was an -- It</p> <p>16 was -- Did you consider it part of your job to</p> <p>17 obtain a written agreement signed by both parties?</p> <p>18 THE WITNESS (In English): Yes. Yes.</p> <p>19 THE INTERPRETER: Yes.</p> <p>20 BY MR. STEWART:</p> <p>21 Q. And who were the parties that you</p> <p>22 wanted a written agreement between?</p>
<p style="text-align: right;">Page 90</p> <p>1 audit.</p> <p>2 Q. And what conclusions were reached</p> <p>3 through the audit?</p> <p>4 A. I think that I recall that many points</p> <p>5 had been improved but there were still -- there</p> <p>6 were still things to do.</p> <p>7 Q. Was there any communication with</p> <p>8 respect to that conclusion to Mr. Murphy?</p> <p>9 A. I do not recall.</p> <p>10 Q. What was the purpose of the meeting in</p> <p>11 April of 1998?</p> <p>12 A. Again, we had to face a situation that</p> <p>13 was not moving forward for the realization of the</p> <p>14 contract and it seemed critical to have a meeting</p> <p>15 to unblock the situation.</p> <p>16 Q. Was the situation -- Is the situation</p> <p>17 that you're referring to the fact that no</p> <p>18 manufacturing agreement had been signed?</p> <p>19 A. More generally, it's the fact that</p> <p>20 everything that was proposed and agreed between</p> <p>21 the party could not find a legal transcription.</p> <p>22 Q. That is, nothing was put in writing?</p>	<p style="text-align: right;">Page 92</p> <p>1 A. As I said previously, it could only be</p> <p>2 Belmac Spain and Ethypharm Spain.</p> <p>3 Q. And what did you do to further your</p> <p>4 goal of getting a written agreement?</p> <p>5 A. As previously, I called upon</p> <p>6 Mr. Murphy and the mother company to obtain a</p> <p>7 meeting between -- between them, us, Belmac, and</p> <p>8 Ethypharm Spain.</p> <p>9 Q. And that was because the people you</p> <p>10 were dealing with at Laboratorios Belmac in Spain</p> <p>11 were not providing the cooperation you needed?</p> <p>12 A. I don't know if we can talk about</p> <p>13 cooperation but they didn't seem to have any</p> <p>14 instructions to sign an agreement.</p> <p>15 Q. Did they ever tell you that they had</p> <p>16 no instructions?</p> <p>17 A. No, because, as I just said, it seemed</p> <p>18 to me that --</p> <p>19 Q. So who attended the meeting?</p> <p>20 MR. BOSTWICK: And this is the -- Just</p> <p>21 for the record, this is the April '98.</p> <p>22 THE WITNESS (IN ENGLISH): '98.</p>

23 (Pages 89 to 92)

<p style="text-align: right;">Page 93</p> <p>1 MR. BOSTWICK: Yeah.</p> <p>2 THE WITNESS (IN ENGLISH): As -- On --</p> <p>3 On -- On the Belmac side, Clemente Gonzalez. I</p> <p>4 think Adolfo Herrera was there and, also,</p> <p>5 Berenguer. On the Bentley side, Jim Murphy. On</p> <p>6 our side, myself and Adolfo De Basilio. And maybe</p> <p>7 Domingo Barnabe was there because every time we</p> <p>8 had a meeting --</p> <p>9 THE INTERPRETER: It was in English so</p> <p>10 I don't have to translate.</p> <p>11 As usual at each meeting we felt the</p> <p>12 need to -- to have a history; that is, to repeat</p> <p>13 everything that had been said and done before.</p> <p>14 That's why I think Domingo Barnabe was there</p> <p>15 because he was the one who had put together the</p> <p>16 new manufacturing.</p> <p>17 MR. STEWART: As -- I'm sorry. He was</p> <p>18 the one who had put together?</p> <p>19 THE WITNESS: Put together, set up,</p> <p>20 the new manufacturing/fabrication business.</p> <p>21 THE WITNESS (IN ENGLISH): New</p> <p>22 formulation.</p>	<p style="text-align: right;">Page 95</p> <p>1 A. In St. Cloud.</p> <p>2 MR. BOSTWICK: I'll leave it to you,</p> <p>3 Craig, but if you want to finish this topic or if</p> <p>4 you want to break before getting into it, it's</p> <p>5 about 1:15 which is what you had said before, but</p> <p>6 it's -- it's your --</p> <p>7 MR. STEWART: Well --</p> <p>8 MR. BOSTWICK: It just depends on what</p> <p>9 you want to.</p> <p>10 MR. STEWART: Let's go off the record</p> <p>11 just for a moment. Sure.</p> <p>12 THE VIDEOGRAPHER: The time is</p> <p>13 13:18:35. Off the record.</p> <p>14 (Discussion off the record.)</p> <p>15 THE VIDEOGRAPHER: On the record. The</p> <p>16 time is 13:19:17.</p> <p>17 BY MR. STEWART:</p> <p>18 Q. Okay. So what happened? What</p> <p>19 occurred at the April 1998 meeting?</p> <p>20 A. I don't recall all the details but the</p> <p>21 following points were discussed.</p> <p>22 First, we had a reminder of all that</p>
<p style="text-align: right;">Page 94</p> <p>1 THE WITNESS: New formulation, okay.</p> <p>2 BY MR. STEWART:</p> <p>3 Q. You say the "new formulation." What</p> <p>4 do you mean by "new formulation"?</p> <p>5 A. A stable formulation that was put in</p> <p>6 place beginning in 1995 and adapted to a new</p> <p>7 manufacturing equipment. GS turbines.</p> <p>8 Q. GS what?</p> <p>9 A. Turbine, turbine.</p> <p>10 THE WITNESS (IN ENGLISH): Drums:</p> <p>11 Turbines. Turbines.</p> <p>12 THE INTERPRETER: Turbines, drums,</p> <p>13 and -- pans.</p> <p>14 So I think that's why we were asked to</p> <p>15 be there. Maybe there was Marcelle Gavaille but</p> <p>16 I'm not sure. And -- And, of course, Gerard Leduc</p> <p>17 and Patrice Debregeas probably made appearances</p> <p>18 during the meeting but did not stay permanently</p> <p>19 for the whole -- continuously.</p> <p>20 BY MR. STEWART:</p> <p>21 Q. Where was -- Where was the meeting</p> <p>22 held?</p>	<p style="text-align: right;">Page 96</p> <p>1 had been done and the problems that had arisen, of</p> <p>2 all the solutions that were already put in place,</p> <p>3 warranties on the consistency of manufacturing</p> <p>4 quality of Omeprazole, the new formula, the new</p> <p>5 equipments, the new specifications for raw</p> <p>6 materials, and the number of lots manufacturing</p> <p>7 each -- manufactured each month.</p> <p>8 Since we restated the --</p> <p>9 THE WITNESS (IN ENGLISH):</p> <p>10 Requirements.</p> <p>11 THE INTERPRETER: -- requirements that</p> <p>12 had been indicated many times. Several. The</p> <p>13 first time after our termination letter, during my</p> <p>14 meeting with Mr. Murphy, and after that, and</p> <p>15 during our different exchanges, our concern about</p> <p>16 the confidentiality about what had been</p> <p>17 transmitted to Belmac, the technology and the</p> <p>18 know-how; therefore, to prepare a document for the</p> <p>19 recognition of the ownership by Ethypharm of all</p> <p>20 these points and the compliance by Belmac about</p> <p>21 the confidentiality of all that had been</p> <p>22 transmitted. The topic was a very -- very</p>

24 (Pages 93 to 96)

<p style="text-align: right;">Page 97</p> <p>1 delicate topic. Omeprazole had become an 2 important product or was to become an important 3 product; that is to say, that Omeprazole was very 4 important product for its inventor and was to 5 become a very important product for Ethypharm 6 which was manufacturing it but also for Belmac 7 which was selling this product under its trademark 8 and Ethypharm wanted to make sure that everything 9 that had to do with industrial and intellectual 10 property was well protected. And this was in fact 11 more important for us than to reach an agreement 12 on the manufacturing price. 13 BY MR. STEWART: 14 Q. Can I just interrupt just one moment. 15 Did you have a concern that Ethypharm's 16 intellectual property had not been protected prior 17 to this meeting? 18 A. No. No, that was a preventative 19 action, measure, and so the -- to finish, it was 20 then more -- more important to us to protect this 21 intellectual property than to reach a written 22 agreement on the manufacturing price since we were</p>	<p style="text-align: right;">Page 99</p> <p>1 Referring to Exhibit 6, the proposal 2 by Mr. Gonzalez -- 3 THE WITNESS (IN ENGLISH): Mm-hmm. 4 BY MR. STEWART: 5 Q. -- were the prices proposed by 6 Mr. Gonzalez accepted? 7 A. These prices were the prices that we 8 had ourselves proposed during previous meetings 9 and, therefore, they were accepted. 10 Q. And these were the prices that 11 Ethypharm would pay to Laboratorios Belmac; 12 correct? 13 A. That is correct. Per manufacturing, 14 not for each product. 15 MR. STEWART: Thank you. Okay. Why 16 don't we take our luncheon break. 17 THE VIDEOGRAPHER: The time is 18 13:27:21. Off the record. 19 (Lunch recess.) 20 THE VIDEOGRAPHER: On the record. The 21 time is 14:22:29. 22 ...</p>
<p style="text-align: right;">Page 98</p> <p>1 already functioning under the terms that had been 2 accepted by Mr. Gonzalez in his letter. And I 3 think at this meeting we submitted a document 4 to -- for Mr. Murphy and Mr. Gonzalez's signature 5 with respect to the protection of confidentiality 6 and intellectual property. 7 Q. Was that document signed? 8 A. This document was discussed and -- and 9 we -- we made some changes to it and we sent it to 10 Mr. Murphy and Mr. Gonzalez something like two 11 days after the meeting. I don't recall exactly. 12 Immediately after the meeting but I did not see a 13 signed copy of this document. 14 Q. Have you completed your testimony as 15 to what occurred at that meeting? 16 MR. BOSTWICK: Objection to form. 17 THE WITNESS: For the moment I don't 18 remember anything else about what happened but I'm 19 ready to answer other questions. 20 BY MR. STEWART: 21 Q. Okay. I just have one question now 22 and then we can break for lunch.</p>	<p style="text-align: right;">Page 100</p> <p>1 BY MR. STEWART: 2 Q. Now, Mr. Dubois, before the break, you 3 were telling us your recollection of what occurred 4 at the meeting in April 1998. Do you recall that? 5 THE WITNESS (IN ENGLISH): Mm-hmm. 6 THE INTERPRETER: Yes. 7 BY MR. STEWART: 8 Q. And in your testimony, you said that 9 you had a particular concern over the 10 confidentiality of Ethypharm's technology and 11 know-how; is that correct? 12 MR. BOSTWICK: Objection to 13 characterization. 14 THE WITNESS: That's correct. 15 BY MR. STEWART: 16 Q. And I believe your testimony was that 17 you prepared a document to be signed Belmac. Am I 18 correct in that? 19 A. Yeah, that is correct except that this 20 document had to be discussed first. 21 Q. Okay. And who -- Did you give a draft 22 of that document to anyone?</p>

25 (Pages 97 to 100)

<p style="text-align: right;">Page 101</p> <p>1 A. I think this document was prepared by 2 Mrs. Joannesse and then it was given during the 3 meeting, during the exchanges, and then it had to 4 be reviewed later by Mr. Leduc. 5 You must remember that Gerard Leduc is 6 trained as a consultant in the patent and the 7 industry -- counsel. 8 Q. And what happened after Mr. Leduc 9 reviewed that document? 10 A. Like I said before, I think it was 11 sent in the days -- in the few days that followed 12 the meeting both to Mr. Gonzalez and to 13 Mr. Murphy. 14 Q. And did that -- Was that document ever 15 signed? 16 A. I don't know since I haven't seen a 17 signed copy but we were in agreement during the 18 meeting about its contents. There hadn't been any 19 rejection. 20 Q. Did anyone at Laboratorios Belmac make 21 any comments or -- written comments or changes to 22 the document prepared by Rosaline Joannesse?</p>	<p style="text-align: right;">Page 103</p> <p>1 Exhibit 10. Can you tell us what that is? 2 A. Apparently, it's a statement, a 3 certificate, by -- from Laboratorios Belmac signed 4 by Mr. Gonzalez but I don't know who is the 5 recipient of this certificate. 6 Q. Who drafted the certificate? 7 A. I don't know. 8 Q. Have you seen this document before? 9 A. No, I don't recall seeing this 10 document. 11 Q. In your position as vice president of 12 operations, did you, from time to time, ask that 13 confidentiality agreements be signed by 14 Laboratorios Belmac? 15 A. I think that we asked several times, 16 several individuals from Belmac, to sign 17 confidentiality agreements but there was no 18 general agreement until the one that was -- 19 THE WITNESS (IN ENGLISH): No, I said 20 in the absence. 21 THE INTERPRETER: In the ab -- Yeah. 22 That's right. I'm sorry. In the absence of a</p>
<p style="text-align: right;">Page 102</p> <p>1 A. I don't think so. 2 MR. STEWART: Like to mark as the next 3 three exhibits a document on Belmac stationery, 4 EP 008092. 5 (The reporter marked Exhibit 10.) 6 MR. STEWART: And the next document, a 7 document which -- 8 (Conferring.) 9 MR. STEWART: -- which has Bates 10 numbers 000602. 11 (The reporter marked Exhibit 11.) 12 MR. STEWART: And the third document 13 which has a date of October 2 of 1998, Ethypharm 14 document number 008124. 15 THE REPORTER: May I have that paper 16 clip or do you need it? 17 (The reporter marked Exhibit 12.) 18 MR. STEWART: So these are 10, 11 and 19 12? 20 THE REPORTER: Yes. 21 BY MR. STEWART: 22 Q. Mr. Dubois, I'd like to start with</p>	<p style="text-align: right;">Page 104</p> <p>1 general confidentiality agreement. 2 THE WITNESS (IN ENGLISH): We asked 3 them to sign the individual. 4 THE INTERPRETER: Yeah. They had to 5 sign individual agreements. 6 BY MR. STEWART: 7 Q. And the agreement that you were 8 referring to that was distributed at the 9 April 1998 meeting was a general agreement; is 10 that correct? 11 A. That is correct. This agreement had 12 been -- was to be signed both by Belmac and by 13 Bentley. 14 Q. Why did you have the agreement -- Oh, 15 let me withdraw that. 16 Was there a -- Was there a place for 17 the signature of a representative of Bentley on 18 the document? 19 A. If I recall correctly, both Mr. Murphy 20 from Bentley and Mr. Gonzalez from Belmac were 21 mentioned in the document -- in the body of the 22 document.</p>

26 (Pages 101 to 104)

<p style="text-align: right;">Page 105</p> <p>1 Q. Why did you want to have Bentley's 2 signature on the confidentiality agreement? 3 A. Since we had discussions in our 4 relations with -- with Mr. Murphy, we realized 5 that Bentley had to know -- 6 THE INTERPRETER: Oh. Bentley had to 7 know -- Bentley had to know what was transmitted 8 to Belmac by Ethypharm. 9 THE WITNESS (In English): Or "knew" 10 rather than "had to know." 11 THE INTERPRETER: Bentley knew what 12 was transmitted by Belmac -- 13 THE WITNESS (IN ENGLISH): To Belmac. 14 THE INTERPRETER: To Belmac by 15 Ethypharm. 16 BY MR. STEWART: 17 Q. And is it fair to say that you did not 18 consider the signature by Laboratorios Belmac to 19 be sufficient with respect to confidentiality, a 20 confidentiality obligation by Bentley? 21 MR. BOSTWICK: Objection. Objection 22 to characterization.</p>	<p style="text-align: right;">Page 107</p> <p>1 seen this document before? 2 A. I don't recall precisely. 3 Q. Do you recall that there was a 4 confidentiality agreement that Belmac requested 5 Ethypharm Spain to sign? 6 A. No. 7 Q. Turning to page 000602 -- 8 A. I only see that this agreement was 9 related to products made from the microgranules 10 made by Ethypharm. 11 THE WITNESS (IN ENGLISH): No. 12 THE INTERPRETER: Oh. Sold -- I'm 13 sorry -- sold by Belmac to Ethypharm. 14 THE WITNESS (IN ENGLISH): No. 15 THE INTERPRETER: Sold from Ethypharm 16 to Belmac. 17 THE WITNESS (In English): No. 18 THE INTERPRETER: Okay. Sorry. 19 Products -- The products sold by Belmac 20 under their brand name, Omeprazole, are made from 21 granules made by Ethypharm. And this product was 22 to be sold by Ethypharm to its partner, Leciva. I</p>
<p style="text-align: right;">Page 106</p> <p>1 THE WITNESS: It is customary to have 2 all the companies that -- that must know the 3 confidential documents sign the confidentiality 4 paper. 5 BY MR. STEWART: 6 Q. Did you recognize then that in 7 addition to dealing with Laboratorios Belmac, at 8 that time you were also dealing with Bentley? 9 A. But it is not at that time that I 10 realized that but when we had managed to unblock 11 the situation through the discussions with 12 Mr. Murphy from Bentley. 13 MR. BOSTWICK: Mr. Dubois, when you 14 have a long answer, you may want to shorten it a 15 little bit -- 16 THE WITNESS (IN ENGLISH): Yes. 17 MR. BOSTWICK: -- so he's having a 18 little less difficulty. 19 THE WITNESS (IN ENGLISH): Yeah. 20 Yeah. 21 BY MR. STEWART: 22 Q. And turning to Exhibit 11, have you</p>	<p style="text-align: right;">Page 108</p> <p>1 remember that we had negotiated for the Omeprazole 2 license to -- the -- the sale of the Omeprazole 3 license to -- to Leciva but I was not usually 4 involved in the details of this agreement. 5 It was Ethy -- Ethypharm Spain that was 6 dealing with its customers -- its customers. 7 BY MR. STEWART: 8 Q. So is it your testimony that you were 9 not involved in the preparation of this -- of this 10 agreement; that is, Exhibit 12? 11 THE INTERPRETER: Did you say 12? 12 MR. STEWART: I said -- I'm sorry. I 13 misspoke. Exhibit 11. 14 THE WITNESS (IN ENGLISH): No. 15 THE INTERPRETER: No, I was not 16 involved in the preparation of this document which 17 was concerning Ethypharm Spain and one of its 18 customers. 19 BY MR. STEWART: 20 Q. Do you have any knowledge as to 21 whether Mr. Murphy directed that this 22 confidentiality agreement be drafted and signed</p>

27 (Pages 105 to 108)

Page 109

1 by -- drafted and then signed by Ethypharm?

2 A. I don't see why it would have been the
3 case because in this case it was Ethypharm that
4 was committing -- committing to comply with the
5 confidentiality in order to have access to
6 documents allowing registration by its client
7 Leciva.

8 Q. How do you spell Leciva?

9 A. It's L-e-c-i-v-a but it's -- In Czech
10 the C probably has some kind of a little tilde or
11 accent on it.

12 Q. And please look at Exhibit 12. Did
13 you have any involvement in the preparation of
14 Exhibit 12?

15 A. No, I don't remember this.

16 Q. Have you seen Exhibit -- Have you seen
17 Exhibit 12 before?

18 A. I do not remember.

19 Q. Following the meeting on April -- in
20 April of 1998 did you have any -- did you have
21 further communications with Mr. Murphy?

22 A. I don't recall any meeting precisely

Page 110

1 and -- mail -- Mail, it's possible.

2 Q. Were there any -- any events or crises
3 that you believed required you to contact
4 Mr. Murphy?

5 A. After '98?

6 Q. Yes.

7 A. No, we were working at the time on the
8 manufacturing but I think I recall that in 1999
9 there were some problems following the publication
10 by a Spanish newspaper by Belmac -- Yeah. I think
11 it was in 1999 -- by Belmac on its product,
12 Belmazol.

13 Q. Were you involved with that issue?

14 A. Yes.

15 Q. What was your involvement?

16 A. Adolfo De Basilio sent me the
17 newspaper articles. It were -- They were articles
18 and advertisements -- statements, then, by Belmac
19 on the Belmazol product that they were launching
20 vigorously. I think they had obtained a new
21 reimbursement price and because of a -- probably,
22 a -- a price war with the -- with the

Page 111

1 competition -- they had obtained a reimbursement

2 price that was lower than that of the competitors.

3 Q. Reimbursement price from whom?

4 A. By the Spanish Social Security to the
5 patient or government's health insurance --
6 government's health insurance. This allowed
7 Belmac to start a -- to launch a very aggressive
8 advertising campaign and at the same time to make
9 some noise about Belmac Spain. Our issue was that
10 they were saying in these articles that the
11 technology was -- the technology was theirs or,
12 rather, that they were manufacturing Omeprazole
13 follow -- following their technology in their
14 plant without mentioning Ethypharm in any way,
15 neither as the true manufacturer which we were nor
16 as inventors of the technology. And I think at
17 that time, with Patrice Debregeas, a letter was
18 sent which we had discussed together but I know
19 the one who signed it. He is the one who sent it
20 to Jim Murphy.

21 Q. He is -- He is who? He's who?

22 A. Patrice Debregeas.

Page 112

1 Q. Following the April 1998 meeting, did
2 you have any further meetings with Adolfo Herrera?

3 A. Yes, I think in -- once or twice
4 during -- during a trip to Madrid.

5 Q. What were the -- What were the
6 substance of those meetings?

7 A. I don't remember the details. Adolfo
8 Herrera had become the general manager of Belmac.
9 The first visit -- The first visit was then a
10 friendly visit to make sure that we would be able
11 get along with Adolfo Herrera and I think I saw
12 him again in -- in a future trip without any
13 specific agenda for the meeting.

14 Q. Okay. Did you understand that as
15 general manager of Laboratorios Belmac -- that
16 Adolfo Herrera had the authority to take actions
17 on behalf of Belmac?

18 MR: BOSTWICK: Objection. Vague.
19 What actions?

20 THE WITNESS: I think he was acting as
21 Belmac's general manager. I think at the time his
22 responsibilities, his concerns, were to -- to

28 (Pages 109 to 112)

<p style="text-align: right;">Page 113</p> <p>1 improve Belmac's sales among the things for the -- 2 through the launch of Belmazol. 3 BY MR. STEWART: 4 Q. Did you understand that Adolfo Herrera 5 had the authority to make agreements on behalf of 6 Laboratorios Belmac? 7 MR. BOSTWICK: Objection. Vague. 8 THE WITNESS: As far as the -- the -- 9 the -- the agreements that we were wishing, in 10 particular, the finalization of a manufacturing 11 agreement that was still not signed, based on my 12 prior experience with Clemente Gonzalez, it was 13 more a wait-and-see policy. 14 THE WITNESS (IN ENGLISH): On my part. 15 THE INTERPRETER: On my part. 16 And I -- And I wanted to know if we 17 would really be able to conclude with Adolfo 18 Herrera; whereas, we hadn't been able to do it 19 with Clemente Gonzalez. 20 BY MR. STEWART: 21 Q. Yes, but did you -- did you believe 22 that Adolfo Herrera himself had the authority to</p>	<p style="text-align: right;">Page 115</p> <p>1 MR. STEWART: And one document which 2 has as its title, Carta de Compromiso de Compra, 3 with Ethypharm number, 004863. 4 BY MR. STEWART: 5 Q. Have you seen Exhibit 13 before? 6 A. This document was made -- was done 7 after I left Ethypharm. 8 Q. Do you recognize the signature of 9 Adolfo Herrera on this agreement? 10 A. It's possible. I -- I am not aware of 11 the signature. 12 Q. Do you recognize the signature of 13 Adolfo De Basilio for Laboratorios Ethypharm S.A.? 14 A. Yes. 15 Q. Did Jim Murphy ever tell you that 16 Adolfo Herrera -- Herrera had the authority to 17 enter into agreements on behalf of Bentley 18 Pharmaceuticals? 19 A. No, Bentley, Bentley Pharmaceuticals. 20 Q. Yes. 21 A. No. Sorry. 22 Q. Did you understand at any time that</p>
<p style="text-align: right;">Page 114</p> <p>1 enter into the -- enter into an agreement on 2 behalf of Laboratorios Belmac? 3 MR. BOSTWICK: Objection. Vague. 4 THE WITNESS: I had no more reason to 5 believe that, to believe that, than I believed it 6 from Clemente Gonzalez but after that point, I 7 hadn't seen it so I was not convinced. 8 BY MR. STEWART: 9 Q. Are you aware that there is a written 10 agreement that -- between Ethypharm Spain and 11 Laboratorios Belmac that is signed by Adolfo 12 Herrera? 13 A. I don't know which agreement it's 14 about. 15 MR. STEWART: Let me show you two 16 documents, one document which has the Bates number 17 of BEL000548. Sorry. Yeah, 548. 18 (The reporter marked Exhibit 13.) 19 MR. STEWART: Okay. And what exhibit 20 number is that? 21 THE REPORTER: 13. 22 THE WITNESS (IN ENGLISH): 13.</p>	<p style="text-align: right;">Page 116</p> <p>1 Adolfo Herrera had the authority to enter into 2 agreements with Ethypharm on behalf of Bentley 3 Pharmaceuticals, Inc.? 4 A. No, of course not. 5 Q. And did you -- Did Mr. Murphy ever 6 tell you that Clemente Gonzalez had authority to 7 make agreements on behalf of Bentley 8 Pharmaceuticals, Inc., or on behalf of Belmac 9 Corporation? 10 A. No, of course not. 11 Q. And did you have an un -- did you -- 12 did you ever have an understanding that Clemente 13 Gonzalez could enter into agreements on behalf of 14 Bentley Pharmaceuticals, Incorporated? 15 A. No, but I don't see what this has to 16 do with these documents. 17 MR. STEWART: I -- I didn't say that 18 it did. 19 THE WITNESS (IN ENGLISH): Show me the 20 document. 21 BY MR. STEWART: 22 Q. When you were still at Ethypharm, did</p>

29 (Pages 113 to 116)

<p style="text-align: right;">Page 117</p> <p>1 you ever hear anyone at Ethypharm say that they</p> <p>2 believed Bentley Pharmaceuticals had directed</p> <p>3 Laboratorios Belmac to steal Ethypharm's secret</p> <p>4 technology?</p> <p>5 A. No, I didn't hear such things.</p> <p>6 Q. Did you ever hear anyone say that they</p> <p>7 believed that Jim Murphy had directed Laboratorios</p> <p>8 Belmac to steal Ethypharm's secret technology?</p> <p>9 A. No, of course not.</p> <p>10 Q. What was the disagreement that you had</p> <p>11 with Mr. Debregeas which led to your termination?</p> <p>12 A. Mr. Debregeas wanted to take on the</p> <p>13 manufacturing of very large quantities of</p> <p>14 Vitamin C as contract manufacturer for a large</p> <p>15 laboratory and I was totally opposed to that and I</p> <p>16 said it publicly.</p> <p>17 MR. STEWART: Give me just a moment.</p> <p>18 Let's go off the record just a moment.</p> <p>19 THE VIDEOGRAPHER: The time -- This</p> <p>20 ends Tape No. 2 of the Dubois deposition. The</p> <p>21 time is fifteen hundred hours, nine seconds. Off</p> <p>22 the record.</p>	<p style="text-align: right;">Page 119</p> <p>1 extend my thanks and I'm -- and I'm sure the</p> <p>2 thanks of the other party as well for your coming</p> <p>3 in, especially given that you're no longer with</p> <p>4 either of these companies.</p> <p>5 A. Thank you.</p> <p>6 Q. When Mr. Murphy introduced himself to</p> <p>7 you, did he give you a business card?</p> <p>8 A. Yes, I remember having business cards</p> <p>9 from Jim Murphy.</p> <p>10 Q. And where was the business card from?</p> <p>11 What company?</p> <p>12 A. The first one, I'm not sure if it was</p> <p>13 made from Belmac Corporation but I think it was</p> <p>14 from Bentley because it was in '97 -- I think in</p> <p>15 February '97 -- and I think at that time Bentley</p> <p>16 was the identity of the company.</p> <p>17 In fact, I recall -- I remember</p> <p>18 precisely that during this meeting, Mr. Murphy</p> <p>19 told me that he was raising funds for Bentley.</p> <p>20 Q. Okay. And just so we're absolutely</p> <p>21 clear, when you say Belmac Corporation, you mean</p> <p>22 Belmac in the U.S.A.?</p>
<p style="text-align: right;">Page 118</p> <p>1 (Recess.)</p> <p>2 (The reporter marked Exhibit 14.)</p> <p>3 THE VIDEOGRAPHER: On the record with</p> <p>4 Tape No. 3 of the testimony of Claude Dubois in</p> <p>5 the matter of Ethypharm versus Bentley</p> <p>6 Pharmaceuticals. The date is July 12th, 2006.</p> <p>7 The time is 15:02:03.</p> <p>8 MR. STEWART: Mr. Dubois, I have no</p> <p>9 further questions at this time. I may have a few</p> <p>10 questions after Mr. Bostwick has his turn with his</p> <p>11 examination of you. Thank you.</p> <p>12 THE WITNESS: Thank you.</p> <p>13 MR. BOSTWICK: Shall we go off the</p> <p>14 record?</p> <p>15 THE VIDEOGRAPHER: The time is</p> <p>16 15:02:35. Off the record.</p> <p>17 (Recess.)</p> <p>18 THE VIDEOGRAPHER: On the record. The</p> <p>19 time is 15:23:43.</p> <p>20 EXAMINATION BY COUNSEL FOR THE PLAINTIFFS</p> <p>21 BY MR. BOSTWICK:</p> <p>22 Q. Good afternoon, Mr. Dubois. And I</p>	<p style="text-align: right;">Page 120</p> <p>1 A. Yes.</p> <p>2 Q. Did he ever give you a business card</p> <p>3 from Laboratorios Belmac?</p> <p>4 A. Never.</p> <p>5 Q. What position did you understand that</p> <p>6 Mr. Murphy held at Bentley Pharmaceuticals?</p> <p>7 THE WITNESS (IN ENGLISH): Chairman</p> <p>8 and CEO.</p> <p>9 THE INTERPRETER: Chairman and CEO.</p> <p>10 Yeah.</p> <p>11 BY MR. BOSTWICK:</p> <p>12 Q. And is that consistent with the</p> <p>13 business card that Mr. Murphy gave to you?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. I'd ask you to look at Exhibit</p> <p>16 No. 1 in that pile. I believe that's No. 2.</p> <p>17 THE WITNESS (IN ENGLISH): Yes.</p> <p>18 BY MR. BOSTWICK:</p> <p>19 Q. Is it there?</p> <p>20 A. I don't know where No. 1 went to.</p> <p>21 MR. BOSTWICK: Check -- Check behind</p> <p>22 No. 2. Is it --</p>

30 (Pages 117 to 120)

<p style="text-align: right;">Page 121</p> <p>1 THE WITNESS (IN ENGLISH): Oh, wait.</p> <p>2 MR. BOSTWICK: Is it stuck back there?</p> <p>3 Mine has as well.</p> <p>4 BY MR. BOSTWICK:</p> <p>5 Q. And you'll recall Mr. Stewart asked</p> <p>6 you some questions about this document?</p> <p>7 A. Yes.</p> <p>8 Q. And as I understand your testimony,</p> <p>9 this letter in January 20th, 1997 from Adolfo De</p> <p>10 Basilio to Clemente Gonzalez told Laboratorios</p> <p>11 Belmac that Bentley -- I'm sorry -- that Ethypharm</p> <p>12 was prepared to terminate the relationship; is</p> <p>13 that correct?</p> <p>14 MR. STEWART: Objection. Document</p> <p>15 speaks for itself.</p> <p>16 BY MR. BOSTWICK:</p> <p>17 Q. You can answer.</p> <p>18 A. Yes, that is correct.</p> <p>19 Q. Okay. What were the reasons that</p> <p>20 Ethypharm had come to the point where they were</p> <p>21 prepared to terminate the relationship between --</p> <p>22 with -- with the Spanish entity?</p>	<p style="text-align: right;">Page 123</p> <p>1 that the Exhibit 2 is the response that came from</p> <p>2 Belmac and Bentley or -- Strike that.</p> <p>3 I believe you testified already that</p> <p>4 Exhibit 2 is the response that came to the letter</p> <p>5 marked as Exhibit 1; is that correct?</p> <p>6 A. That's correct. The reference is</p> <p>7 mentioned in the letter.</p> <p>8 Q. Okay. And whose letterhead does that</p> <p>9 response come on?</p> <p>10 THE WITNESS (IN ENGLISH): Bentley</p> <p>11 Pharmaceutical, Inc.</p> <p>12 BY MR. BOSTWICK:</p> <p>13 Q. Okay. And the "From" line -- who --</p> <p>14 who is sending that letter?</p> <p>15 A. Mr. Murphy himself.</p> <p>16 Q. And what does Mr. Murphy himself say</p> <p>17 about his own position, the -- the position that</p> <p>18 he's writing this letter as?</p> <p>19 MR. STEWART: Objection. The language</p> <p>20 in the letter is evident from the face of the</p> <p>21 letter. Document speaks for itself.</p> <p>22 ...</p>
<p style="text-align: right;">Page 122</p> <p>1 A. These are the reasons expressed in</p> <p>2 this letter, mainly, the fact -- mainly, the fact</p> <p>3 that we couldn't agree on a manufacturing price</p> <p>4 that -- that would be acceptable for Ethypharm and</p> <p>5 the issue of compliance with the GMP -- GMP</p> <p>6 standards which had become especially critical</p> <p>7 after the audit. The issue of the improvement of</p> <p>8 the manufacturing mark -- manufacturing margin</p> <p>9 depended also upon the manufacturing price.</p> <p>10 Q. Was this a critical point in the</p> <p>11 relationship between Ethypharm and Bentley and</p> <p>12 Belmac?</p> <p>13 A. Quite. We were forced to terminate</p> <p>14 the relationship and we -- we were then unable to</p> <p>15 manufacture Omeprazole in Spain.</p> <p>16 Q. Okay. Let me have you look at</p> <p>17 Exhibit 2.</p> <p>18 MR. STEWART: Sorry. Was that -- Was</p> <p>19 that "unable to manufacture"?</p> <p>20 THE WITNESS: Mm-hmm. Yes.</p> <p>21 BY MR. BOSTWICK:</p> <p>22 Q. And I believe you testified already</p>	<p style="text-align: right;">Page 124</p> <p>1 BY MR. BOSTWICK:</p> <p>2 Q. You can -- You can answer that</p> <p>3 question.</p> <p>4 A. He -- He states himself as being the</p> <p>5 chairman and CEO.</p> <p>6 Q. Of Bentley Pharmaceuticals, Inc., in</p> <p>7 the United States?</p> <p>8 MR. STEWART: Objection.</p> <p>9 THE WITNESS: I assume so since it is</p> <p>10 on the letterhead from Bentley Pharmaceuticals.</p> <p>11 BY MR. BOSTWICK:</p> <p>12 Q. And is this consistent with the</p> <p>13 business card Mr. Murphy gave to you when he</p> <p>14 introduced himself?</p> <p>15 A. Yes.</p> <p>16 Q. I want to refer your attention to the</p> <p>17 first and second lines of this letter. And I'll</p> <p>18 just read you the first and second lines.</p> <p>19 Dear Patrice, I am writing with regard</p> <p>20 to the fax that I received from your Spanish</p> <p>21 office. I am confused because ever since I</p> <p>22 assumed control of Laboratorios Belmac, I have</p>

31 (Pages 121 to 124)

<p style="text-align: right;">Page 125</p> <p>1 received nothing but extremely positive comments 2 from your Spanish staff, specifically Senior 3 Basilio, who said that the Laboratorio -- I'm 4 sorry -- that the Belmac operation is now more 5 efficient, more cooperative, more pleasant to work 6 with, and beyond this; he noted our high degree of 7 sincerity and integrity. 8 Now, as I understand it, Mr. -- 9 Mr. Murphy at Bentley Pharmaceuticals is 10 responding to Ethypharm's statement that it will 11 likely terminate the relationship; correct? 12 A. Correct. 13 Q. And what does his comment that ever 14 since he assumed Laboratorios -- control of 15 Laboratorios Belmac -- indicate to you about 16 whether Bentley Pharmaceuticals intends to direct 17 and control the negotiations with Ethypharm? 18 MR. STEWART: Objection. 19 Objection. Are you asking him for his 20 understanding today or his understanding at the 21 time of the letter, and if the latter -- 22 MR. BOSTWICK: His understanding at</p>	<p style="text-align: right;">Page 127</p> <p>1 That's an "RJ" for Rosaline Joannesse -- 2 A. Yes. 3 Q. Okay. Not an RT? 4 A. No. 5 THE WITNESS (IN ENGLISH): No "RT." 6 THE INTERPRETER: So upon receipt of 7 this letter, my understanding was that Bentley and 8 Mr. Murphy wanted to reach an agreement and that 9 it was with Mr. Murphy that I had to discuss this 10 agreement. 11 MR. BOSTWICK: Now let me show you 12 another document which we have not marked. There 13 you go, and I believe that will be Exhibit 15. 14 (The reporter marked Exhibit 15.) 15 THE WITNESS (IN ENGLISH): 14. Here. 16 You're right. I have a 14 already. 17 (Mr. Bostwick conferred with 18 Mr. Fine.) 19 BY MR. BOSTWICK: 20 Q. Do you recognize that as a fax that 21 was sent to you by Jim Murphy? 22 A. Yes.</p>
<p style="text-align: right;">Page 126</p> <p>1 the time of the letter. 2 MR. STEWART: Okay. Do we have any 3 foundation that he's actually seen the letter? 4 MR. BOSTWICK: You established that. 5 You can answer. 6 THE WITNESS: I can see that I had 7 seen this letter because I'm among the recipients 8 of this letter that had been sent to me by 9 Debregeas since my initials are on it. And I 10 myself transmitted to Eric Igonet. 11 THE WITNESS (IN ENGLISH): Mm-hmm. 12 THE INTERPRETER: Eric Igonet and 13 Rosaline Joannesse. 14 BY MR. BOSTWICK: 15 Q. I see. And that's the occasion in the 16 handwriting at the top of the letter. 17 A. That's correct. 18 Q. "CD" is you? 19 A. Yes. 20 Q. "EI" is Eric Igonet? 21 A. Yes. 22 Q. Oh, and that's -- So -- So "R" -- "R"</p>	<p style="text-align: right;">Page 128</p> <p>1 Q. And this fax confirms -- In this 2 facsimile, am I correct that Jim Murphy is 3 confirming a meeting with you? 4 A. Yes. 5 Q. And what is the heading on the top of 6 that facsimile; in other words, what company is he 7 sending it from? 8 A. "Bentley" is all the way at the top as 9 the sender of the fax; and, of course, Bentley is 10 mentioned in the -- on the fax itself. 11 Q. And did you understand from receiving 12 this fax that Mr. Murphy was responding as the CEO 13 and chairman of Bentley? 14 A. Yes, of course. 15 Q. For purposes of the meeting you were 16 about to have in the U.S.? 17 A. Quite. 18 Q. Okay. Now, I believe -- Did you 19 ultimately meet in the U.S. with -- with 20 Mr. Murphy? 21 A. Yes, on February 3rd, but it did not 22 occur in New York but in Philadelphia.</p>

32 (Pages 125 to 128)